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Abstract 
 
B-lymphopoiesis is characterised by orderly progression through a series of 
stages of differentiation, each of which is associated with specific patterns of protein 
expression and cellular proliferation. These processes require a high degree of 
regulation by the coordinated action of a series of transcription factors that are critical 
for appropriate stage-specific gene expression.  
We describe a novel interaction between Ikaros and Foxp1, two transcription 
factors that are essential for normal B-lymphopoiesis, and which frequently exhibit 
abnormal expression in B-lymphoid malignancy. By co-immunoprecipitation, we have 
demonstrated physical association between the DNA-binding domains of these 
proteins in vivo, which is recapitulated in a cell-free system in vitro. In functional 
experiments, ectopic overexpression of Foxp1 by retroviral infection of pre-B-cells 
resulted in an increased proportion of cells in the G2 phase of the cell cycle. This 
phenotype was associated with increased transcription of Gpr132, a gene which 
encodes the G2A protein that is known to induce G2/M cell cycle arrest in mammalian 
cells. 
The phenotypic effects of Foxp1 overexpression were abolished by co-
infection with Ikaros, which abrogated induction of Gpr132 expression by Foxp1, and 
caused displacement of Foxp1 from the Gpr132 gene, as shown by chromatin 
immunoprecipitation. Co-infection of IK6 (an Ikaros isoform which lacks the Foxp1 
interaction domain and which is frequently expressed in B-cell acute lymphoblastic 
leukaemia) had no effect on Gpr132 expression or Foxp1 occupancy of the Gpr132 
gene, and failed to abolish the phenotypic effects of Foxp1 overexpression. 
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Our results contribute to a growing understanding of transcription factor 
interplay during normal lymphopoiesis, and provide mechanistic insights into the roles 
of Ikaros and Foxp1 in lymphocyte cell cycle homeostasis. In addition, these findings 
may contribute to the understanding of cell cycle dysregulation and chemotherapeutic 
resistance that characterise certain subtypes of acute leukaemia that exhibit aberrant 
expression of these proteins. 
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Chapter 1 
Introduction 
The evolutionary success of virtually all of the species that currently exist on 
earth is predicated upon the ability to combat a range of infectious agents that threaten 
an organism’s survival. In vertebrates, defence against infection is mediated by the 
innate and adaptive immune systems. The generation of mature lymphocytes that 
possess the capacity to recognise a diverse repertoire of foreign antigens is a 
prerequisite for the functioning of the adaptive immune system in mammals (Janeway 
and Medzhitov, 2002). 
Normal lymphoid differentiation is characterised by progression through a 
series of phenotypically-distinct developmental stages and the regulation of stage-
specific gene expression by transcription factors is critical for orderly maturation 
(Busslinger, 2004). It is important to understand the mechanisms that underpin these 
processes, as disorders of lymphopoiesis result in serious human pathology in the 
form of lymphoid malignancy, immune deficiency or autoimmune disease (Knight 
and Cunningham-Rundles, 2006; Pui et al., 2004). 
In this introduction I will first discuss the basic processes involved in gene 
transcription (Section 1.1) and the cell cycle (Section 1.2). The next segments will 
include a general description of B-lymphopoiesis and its transcriptional regulation 
(Section 1.3), and fuller discussion of the roles of the Ikaros and Foxp1 transcription 
factors in lymphoid development (Sections 1.4 and 1.5). In the final part of the 
introduction (Section 1.6), I will discuss how acute lymphoblastic leukaemia (ALL) 
results from dysregulation of gene transcription during lymphoid differentiation.  
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1.1  Regulation of Gene Expression 
As all cells of the human body share identical DNA sequences, phenotypic 
differences arise from diversity in the repertoires of genes expressed by individual 
cells (Levine and Tjian, 2003). Multiple layers of regulation govern the transcription 
of DNA into RNA, while translation of RNA into protein is in turn subject to several 
additional layers of control (Brivanlou and Darnell, 2002). In this section of the 
introduction, I will discuss the processes that directly mediate RNA synthesis (Section 
1.1.1) and the regulation of transcription initiation (Section 1.1.2).  
 
1.1.1 Gene Transcription 
Gene transcription in eukaryotes is mediated by three RNA polymerase 
enzymes (RNA Pol I, II and III). RNA Pol I only transcribes ribosomal RNA (rRNA), 
while RNA Pol III transcribes genes that encode transfer RNA (tRNA), rRNA 
(specifically 5SrRNA) and other small RNA molecules including microRNAs (Oettel 
et al., 1998). Discussion in this section will be confined to the actions of RNA Pol II, 
which transcribes all other eukaryotic genes (Cramer, 2002). 
The first step in gene transcription is the opening and unwinding of a small 
portion of the DNA helix, which allows binding of the transcriptional machinery 
(described below). Following partial unwinding of the DNA molecule, one of the 
exposed strands acts as template for RNA synthesis. Using nucleotide substrates and 
energy obtained from the hydrolysis of high-energy bonds, RNA Pol II synthesises 
nucleotides that are complementary to the DNA strand template (Sawadogo and 
Sentenac, 1990). RNA Pol II extends RNA one base at a time (elongation), while also 
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catalysing the formation of phosphodiester bonds that link nucleotides together. As 
RNA Pol II moves along the DNA molecule, the helix is unwound just ahead of active 
site, thereby exposing new stretches of sequence for complementary base pairing. 
RNA is released almost immediately from the template DNA strand once transcription 
of the complementary bases is completed (Boeger et al., 2005). 
Many additional proteins (comprising at least 100 individual protein subunits) 
are required for initiation of transcription by RNA Pol II (Hahn, 2004). Along with 
RNA Pol II, these proteins constitute the ‘preinitiation complex’. These proteins 
include ‘general’ transcription factors that help to position RNA Pol II correctly at the 
promoter, assist in the DNA strand unwinding, and mediate the release of RNA Pol II 
from the promoter upon commencement of elongation (Dillon, 2006; Matsui et al., 
1980). The largest general transcription factor is TFIID, which comprises a 38kDa 
TATA-binding protein (TBP) subunit (the function of which is discussed in the 
following paragraph) and 13 TBP-associated factors. Other general transcription 
factors include TFIIH, one subunit of which has DNA helicase activity that is 
necessary for DNA strand unwinding. A separate TFIIH subunit mediates 
phosphorylation of the C-terminal domain of RNA Pol II that is necessary for RNA 
elongation. An additional protein complex called Mediator is required for formation of 
the preinitiation complex. Mediator contains approximately 30 protein subunits, some 
of which bind RNA Pol II, while others bind to the transactivation domains of 
transcriptional activator proteins (discussed in Section 1.1.2)  (Reviewed in Kornberg, 
2005). 
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Assembly of the preinitiation complex occurs at the core promoter, which is the 
minimal DNA sequence required to initiate transcription (Smale and Kadonaga, 
2003). The core promoter includes the transcriptional start site, a binding site for RNA 
Pol II, and binding sites for the general transcription factors. An example of the latter 
is the TATA box, which is a sequence rich in thymine and adenine nucleotides that is 
present in 10-20% of all eukaryotic promoters, typically at approximately 25 bases 
upstream of the transcriptional start site. Binding by the TBP subunit of TFIID causes 
distortion of TATA box, which facilitates subsequent steps involved in transcription 
(Juven-Gershon and Kadonaga, 2010). 
An additional factor that influences gene transcription is the physical and 
chemical state of both DNA and associated histone molecules (collectively known as 
chromatin). The basic structural unit of chromatin is the nucleosome, which consists 
of approximately 147 bases of DNA, wrapped around core histone proteins (H2A, 
H2B, H3 and H4) (Luger et al., 1997). Individual nucleosomes are joined by the linker 
histone H1, and are folded into tertiary structures that have variable degrees of 
compaction (Thoma and Koller, 1977). Compression of nucleosomes into dense 
‘heterochromatin’ results in the inhibition of transcription through a variety of 
mechanisms, including blockage of the formation of the preinitation complex on DNA 
(Elgin, 1996). Some genes are located in regions of chromatin that are more ‘open’ 
than others (‘euchromatin’), and transcription therefore proceeds more readily. For 
example, sequences that are flanked by the histone variant H2A.Z are more accessible 
to the transcriptional machinery, and can also be disassembled more rapidly (Jin and 
Felsenfeld, 2007). Local DNA accessibility is also critically affected by chemical 
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modification of the histone tails. For instance, histone acetylation impedes 
nucleosome compaction and causes the chromatin to remain in a more ‘open’, 
transcriptionally-accessible state (Reviewed in Haberland et al., 2009). Conversely, 
trimethylation of lysine at position 9 of the tail of histone H3 (H3K9me3) is 
associated with heterochromatin formation, and inhibition of gene expression 
(Reviewed in Greer and Shi, 2012). The action of many transcriptional activators and 
repressors (discussed in the next section) is mediated by recruitment of chromatin-
remodelling complexes and histone-modifying enzymes that alter local chromatin 
accessibility (Strahl and Allis, 2000).  
 
1.1.2 Regulation of Gene Transcription 
The expression of eukaryotic protein-coding genes is governed by the actions 
of multiple DNA-binding proteins (transcription factors) that bind to specific 
nucleotide sequences, and either activate or repress transcription (Bulger and 
Groudine, 2010). The promoter region of a gene comprises the core promoter and 
upstream elements that include binding sites for transcriptional activators and 
repressors. Many promoters contain recurrent structural features. For example, CpG 
‘islands’ are stretches of 20-50 CpG dinucleotides that are often found within 100 
bases of the transcriptional start site of eukaryotic genes, and methylation of these 
sequences is associated with transcriptional repression (Gardiner-Garden and 
Frommer, 1987). Transcriptional activators and repressors bind to transcriptional 
‘enhancer’ elements, which typically range from 200-1000 bases in length and often 
contain binding sites for several different transcription factors (Arnosti and Kulkarni, 
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2005). Enhancer regions can be located within 1kb (either upstream or downstream) 
of the core promoter, but they can also be found at great distances from the 
transcriptional start site (50 kb or more). In these cases, contact with the promoter is 
mediated by looping of flexible intervening regions of DNA (de Wit and de Laat, 
2012; Dillon et al., 1997). A locus control region (LCR) is the operational definition 
used to describe the full set of positively acting elements (including enhancers) that 
are able to give position-independent and copy-dependent expression in a transgenic 
assay (Li et al., 2002). 
The primary function of transcriptional activators is to regulate the recruitment, 
positioning and modification of RNA Pol II, general transcription factors and the 
Mediator complex at the gene promoter, in order to stimulate transcription initiation. 
Binding of transcriptional activators to enhancer sequences results in recruitment of 
RNA Pol II, and increases transcription rates by approximately 1000-fold (Kadonaga, 
2004). Activators are also involved in the alteration of chromatin structure adjacent to 
the promoter through recruitment of chromatin-remodelling and histone-modifying 
factors, all of which contributes to increased local accessibility of DNA, which 
facilitates assembly of the preinitiation complex (Narlikar et al., 2002). 
Transcriptional repressors may act in several different ways, including 
sequestration of transcriptional activators and/ or general transcription factors by 
direct binding, and recruitment of chromatin-remodelling complexes or histone-
modifying enzymes that generate ‘repressive’ chromatin modifications. In addition, 
direct competition for DNA binding sites and occupancy of gene enhancer elements 
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by repressors can prevent binding of transcriptional activators and subsequent 
transcription initiation (Courey and Jia, 2001; Sabbattini et al., 2001). 
 
1.1.2.1 Transcription Factor Structure 
Transcription factors usually comprise at least two major functional domains. 
DNA binding commonly occurs through regions which contain alpha helices and/ or 
beta sheets that bind to the major groove of DNA. For example, the basic helix-loop-
helix (bHLH) motif contains two alpha helices that bind DNA through conserved 
basic amino acid residues that interact with nucleotide phosphate groups (Murre et al., 
1989). Factors also typically contain a transactivation domain, which usually consists 
of 30-100 amino acids that interact directly with the preinitiation complex and mediate 
acceleration of transcription initiation (Pabo and Sauer, 1992). 
DNA-binding of transcription factors is frequently mediated by ‘zinc finger’ 
domains. Ikaros is one such zinc finger transcription factor (discussed in Section 1.5). 
The description of a zinc finger is based on the original diagrammatic representation 
of the structure, however in vivo it appears that the presence of a central zinc ion 
(Zn2+) causes compaction of the protein through internal folding, thereby allowing 
insertion of the polypeptide into the major groove of DNA (Cox and McLendon, 
2000). The C2H2-type zinc finger (also known as Krüppel-type, after the transcription 
factor in which it was initially described) is the most common type of DNA-binding 
domain in humans. It comprises a 23-26 residue consensus sequence that contains two 
conserved cysteine (C) and two conserved histidine (H) residues, whose side chains 
bind one Zn2+ ion (Krishna et al., 2003). DNA-binding zinc-finger proteins usually 
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contain several zinc fingers that can interact with successive groups of base pairs 
within the major groove of DNA, as the protein wraps around the double helix. The 
extent and strength of the protein-DNA interface may also be increased by 
homodimerisation of zinc finger proteins, and this is typically required for optimum 
transcriptional activity (Klug, 1999). 
‘Leucine zipper’ motifs are also frequently found in eukaryotic transcription 
factors, and are involved in both protein dimerisation and DNA binding. The ‘zipper’ 
consists of two alpha helices which form a short coiled-coil domain that is held 
together by interactions between hydrophobic leucine residues (Alber, 1992). Leucine 
zipper proteins always bind DNA as dimers. Distal to the dimerisation interface, the 
two alpha helices separate to form a Y-shaped structure that allows side chains to 
contact and grip the major groove of DNA (Vinson et al., 1989). Forkhead box protein 
P1 (Foxp1) (Section 1.5) contains a region rich in leucine zipper motifs that is 
believed to mediate protein dimerisation, in addition to a forkhead domain that binds 
DNA (discussed in Section 1.5.1) (Wang et al., 2003). 
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1.2 The Cell Cycle 
The cell cycle describes the processes by which a cell duplicates its entire 
genome and organelles (interphase), and divides into two identical daughter cells 
(mitosis, or ‘M’ phase). Interphase comprises a period of DNA synthesis (‘S’), and 
two ‘gap’ phases (G1 and G2) of increased cellular amino acid and RNA biosynthesis, 
that precede S phase and M phase respectively. Cell cycle progression is mediated by 
cyclin-dependent kinases (CDKs) that are enzymatically inactive unless bound to a 
regulatory cyclin, which also confers substrate specificity (Reviewed in Nigg, 2001). 
Timely phosphorylation of target molecules is therefore largely governed by 
fluctuations in cyclin concentration at different phases of the cycle (Pavletich, 1999). 
At least 13 CDKs and 29 cyclins (and cyclin-related proteins) exist in humans, 
however only a subset are important for cell cycle progression - the interphase CDKs 
(CDK2, CDK4 and CDK6), the ‘mitotic’ CDK (CDK1) and four classes of cyclin (D-, 
E-, A- and B-type)  (Malumbres and Barbacid, 2005). 
This section will describe the eukaryotic cell cycle (Section 1.2.1) and the 
regulatory mechanisms that govern its progression (Section 1.2.2). A schematic 
overview of the cycle is depicted in Figure 1.2.1. In Section 1.2.3, I will discuss how 
cell cycle regulation is frequently disrupted in human malignancies. 
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Figure 1.2.1 Schematic representation of the cell cycle. Phases of the cycle are 
listed within the solid blue arrows. The main cyclins and cyclin-dependent kinases 
(CDKs) involved in cycle progression are shown in green, outside the circle. The 
proteins involved in the major cycle checkpoints are listed in red inside the circle. 
APC/C = Anaphase-promoting complex/ Cyclosome. ATM = ataxia telangiectasia-
mutated. ATR = ataxia telangiectasia and Rad3-related. 
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1.2.1 The Eukaryotic Cell Cycle 
A key event of interphase is the replication of DNA during S phase (Reviewed 
in Diffley, 2004). During G1, mitogenic signals promote expression of D-type cyclins, 
which activate CDK4 and CDK6 (Malumbres and Barbacid, 2001). Phosphorylation 
of retinoblastoma (Rb) protein (which normally represses the activity of E2F 
transcription factors) is the key event in progression to S phase. Phosphorylation by 
CDK4 and CDK6 inhibits Rb interaction with E2F, allowing upregulation of genes 
involved in DNA synthesis (Ekholm and Reed, 2000). E2F factors also induce 
expression of E-type cyclins, which promote CDK2-mediated phosphorylation of key 
regulatory sites in the DNA prereplication complex that in turn results in initiation of 
DNA replication. CDK2 is subsequently activated by A-type cyclins during the later 
stages of S phase, and remains active until the end of G2. A-type cyclins then activate 
CDK1 to stimulate the onset of mitosis (Enserink and Kolodner, 2010). 
At the end of S phase, duplicated DNA molecules are disentangled and 
condensed into pairs of sister chromatids that are held together by cohesin proteins 
(Zou, 2011). Formation of a protein structure called a kinetochore at the chromatid 
centromere is necessary for further cell cycle progression (Kline-Smith et al., 2005). 
Following dissolution of the nuclear envelope, A-type cyclins are degraded and CDK1 
is activated by Cyclin B for the duration of mitosis. Sister chromatids align at the 
central metaphase plate and are attached (via kinetochores) to the mitotic spindle by 
microtubules which emanate from opposing poles of the cell (Lew and Burke, 2003). 
Separation of chromatids during anaphase requires destruction of securin, which 
otherwise inhibits the separase enzyme that mediates proteolysis of cohesin and 
23 
 
release of sister chromatids (Uhlmann et al., 1999). Securin is destroyed through the 
action of the anaphase promoting complex/ cyclosome (APC/C) (Peters, 2006). 
After sister chromatids are pulled apart, the mitotic spindle is disassembled and 
the newly segregated chromosomes are packaged into two separate nuclei during 
telophase. This phase is followed by cytokinesis, which involves separation of the 
duplicated material into two daughter cells (each of which contain nuclei and all 
necessary cellular organelles) through the action of a central contractile ring of actin 
and myosin (Glotzer, 2005). Cytokinesis is triggered by dephosphorylation of CDK 
targets due to APC/C-mediated inactivation of CDKs. Following cytokinesis, the 
nuclear envelope re-forms around segregated chromosomes, and the cell enters a 
stable G1 state of low CDK activity until a new cycle begins (Jeffrey et al., 1995). 
 
1.2.2 Regulation of the Cell Cycle 
The activities of cyclin-CDK complexes are constrained by two major classes 
of protein. Firstly, three related CDK inhibitors (CKIs) – p21CIP, p27KIP1 and p57KIP2 
are most active in late G1 and S-phases, although they also bind later cyclin-CDK 
complexes. The other main group of proteins is the INK4 (INhibitors of Kinase 4) 
family that interact only with CDK4 and CDK6 in mid-G1. The activities of these 
inhibitory molecules are largely dictated by fluctuations in levels of cyclin-CDK 
complexes at different stages of the cell cycle (Sherr, 2001). 
Cell cycle progression is punctuated by several checkpoints that are critical for 
replicative fidelity. Activation of these checkpoints results in cycle arrest until the 
relevant defect is repaired, or cell death (or senescence) if the damage cannot be 
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rectified (Bartek et al., 2004). The first main checkpoint occurs at the G1/S transition, 
when the presence of unreplicated or damaged DNA blocks commitment to cell cycle 
entry. This DNA damage checkpoint involves the sensor kinases ataxia telangiectasia-
mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) proteins, and the 
checkpoint kinases CHK1 and CHK2. Activation of these pathways results in 
increased levels of p21CIP, and inhibition of CDK activators such as Cdc25 
phosphatase. The p53 molecule is a critical mediator of the DNA damage response, 
and is phosphorylated (and therefore protected from Mdm2-mediated degradation) by 
ATM and ATR. In turn, p53 also promotes p21CIP transcription (Levine, 1997).  
The activity of two spindle checkpoints prevents unequal segregation of genetic 
material that would otherwise result in aneuploidy. The spindle assembly checkpoint 
(SAC) monitors correct microtubule attachment to the chromatid kinetochore. 
Incorrect attachment results in inhibition of CDK1 and Cdc20 phosphatase (which is 
required for APC/C activity), thereby preventing entry into anaphase (Musacchio and 
Salmon, 2007). Finally, the spindle position checkpoint relies on feedback from 
cytoplasmic microtubules, and inhibits progression of mitosis (via inhibition of the 
Cdc14 phosphatase) until the correct position is attained (Moore et al., 2009). 
 
1.2.3 Cell Cycle Dysregulation and Malignancy 
Human cancers are typically characterised by uncontrolled cellular 
proliferation and genomic instability, and it is predictable that mutations (both 
inherited and acquired) in key cell cycle molecules are frequently found. Detailed 
discussion of the plethora of abnormalities that have been described lies beyond the 
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scope of this thesis. However discussion of some examples will illustrate several 
mechanisms of oncogenic cell cycle dysregulation. 
Deregulation of cyclin-CDK activity by acquired gene mutation has been 
demonstrated in many human malignancies (Ortega et al., 2002). Several inherited 
cancer predisposition syndromes are caused by mutations in genes encoding proteins 
of the DNA damage checkpoint, including ataxia telangiectasia (ATM), Seckel 
syndrome (ATR) and Li-Fraumeni syndrome (CHK2) (Caldecott, 2008). Acquired 
mutations in these genes, and in the downstream targets of these molecules 
(particularly p53) are very frequent (Kastan and Bartek, 2004). SAC components 
(notably APC/C) are also commonly mutated (Kops et al., 2005). In the context of 
haematological malignancy, recurrent deletions in the INK4 locus are found in 
childhood leukaemia (see Section 1.6). 
In addition, abnormal prolongation of gap phases can allow cancer cells extra 
time to repair DNA damage caused by chemotherapy, thereby allowing them to evade 
checkpoint-mediated cell death. This effect is seen in subsets of leukaemia that exhibit 
G2 arrest following radiation and chemotherapy, which is believed to contribute to 
chemotherapeutic resistance in these cases (Bedi et al., 1995). The results of 
experiments described in this thesis have particular relevance for elucidation of this 
phenomenon.  
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1.3 B-Cell Development 
B-lymphocytes (henceforth referred to as ‘B-cells’) are blood cells which 
express clonally diverse surface immunoglobulin (Ig) receptors that recognise antigen 
as part of the adaptive immune response (LeBien and Tedder, 2008). Historically, the 
prefix ‘B’ denoted the bursa of Fabricius, which was originally described as the 
location of Ig-producing cells in chickens (Cooper et al., 1965). In humans, ‘B’ more 
correctly denotes ‘bone marrow’, which is the predominant site of B-lymphopoieis in 
post-natal life (Raff et al., 1976). 
All mature B-cells express a structurally unique Ig that forms part of the cell 
surface B-cell receptor (BCR). Somatic rearrangement of Ig gene loci during B-
lymphopoiesis (discussed in Section 1.3.1) generates a vast repertoire of Ig molecules 
that enables recognition of a hugely diverse range of antigen configurations. Binding 
of Ig by its cognate antigen results in activation of a hitherto ‘naïve’ B-cell, which 
proliferates and either differentiates into Ig-secreting plasma cells, or participates in a 
germinal centre reaction in secondary lymphoid organs (i.e. lymph nodes and spleen). 
This germinal centre reaction produces the high affinity B-cell clones that constitute 
the memory compartment of the adaptive immune system, which is critical for a 
secondary immune response following antigen re-exposure (Jacob et al., 1991). 
In addition to antigen recognition, B-cells perform several other important 
immune functions (Reviewed in Danilova, 2012), including (but not confined to) 
antigen presentation to T-cells (Janeway et al., 1987), immunomodulatory cytokine 
secretion (Lampropoulou et al., 2008) and regulation of T-cell activation (Bouaziz et 
al., 2007). 
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In common with all blood cells, B-cells are derived from immature precursors 
which, in humans, reside in the fetal liver in pre-natal life, and in the bone marrow 
thereafter. B-cell development proceeds through a series of stages of increasing 
lineage restriction and diminishing differentiation potential. Each of these stages is 
characterised by distinct patterns of cellular proliferation, surface antigen expression 
and recombination status of Ig genes (Busslinger, 2004). These processes will be 
discussed in depth in the remainder of this section of the introduction. 
It should also be noted that two distinct categories of mature B-cells (B-1 and 
B-2) have been defined in the mouse, although the existence of these subsets has not 
been proven in humans. B-2 cells are considered to be mediators of adaptive immunity 
(as described in the preceding paragraphs), while B-1 cells form part of the innate 
immune system, have distinct phenotype and function, and probably differentiate from 
separate haematopoietic precursors (Hardy and Hayakawa, 2001). As most of these 
discrepancies only become relevant following cellular exit from the murine bone 
marrow, developmental differences between B-cell subsets will not be discussed in 
this introduction (Reviewed in Montecino-Rodriguez and Dorshkind, 2012).  
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1.3.1 B-cell differentiation  
All blood cells originate ultimately from haematopoietic stem cells (HSCs), 
which are characterised by their dual capacities for self-renewal and differentiation 
into any haematopoietic cell type. HSCs are defined immunophenotypically by 
expression of c-kit (CD117) and absence of markers of lineage differentiation (Lin-) 
(Spangrude et al., 1988). HSCs give rise to a variety of multipotent progenitors which 
then develop into mature blood cells via a series of intermediate developmental stages. 
The precise differentiation capacity of many of these progenitor cells remains a source 
of ongoing debate. Traditional assumptions regarding an early lymphoid/ myeloid 
dichotomy are now contentious, particularly in the light of recent data showing that 
relatively ‘late’ precursors retain multilineage potential (Doulatov et al., 2010). The 
immunophenotypic and genetic characteristics of most stages of B-cell development 
are however considered to be well-defined. A schematic representation of the current 
consensus is shown in Figure 1.3.1. 
The most primitive lymphoid-specific precursors which develop from HSCs 
are termed ‘early lymphoid progenitors’ (ELP). Precise characterisation of this stage 
of development remains elusive (Hardy et al., 2007). ELPs are usually defined by 
retention of an HSC immunophenotype (CD117+, Lin-) and expression of ‘lymphoid-
type’ gene transcripts such as DNTT and RAG (Igarashi et al., 2002). It has been 
suggested that ELPs may also be discriminated from other early progenitors by an 
increased sensitivity to oestrogen (Medina et al., 2001). Commitment to a lymphoid 
fate has traditionally been considered to occur with progression to a ‘common 
lymphoid progenitor’ (CLP) stage, defined by acquisition of IL-7 responsiveness 
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(indicated by CD127/ IL7Rα positivity) and Sca-1 expression. CLPs have been shown 
to generate all major lymphocyte categories (B-, T-, Natural Killer (NK) and dendritic 
cells), and do not possess myeloid potential (Kondo et al., 1997). It now appears that 
most mature T-cells develop from immature precursors with dual T-cell/myeloid 
potential, and that the majority of the CLP compartment is probably destined for B-
cell development (Allman et al., 2003; Rumfelt et al., 2006). 
Entry into an exclusively B-lymphoid differentiation pathway occurs with the 
onset of expression of the B-cell specific surface antigen, B220 (also known as 
CD45R) at the pro-B-cell stage (Gounari et al., 2002). Pro-B-cells also express CD19, 
which continues to be expressed for all remaining stages of B-lymphopoieis. Some 
minor differences in nomenclature have been used by groups who have described 
alternative paradigms of B-cell development, using similar immunophenotypic 
methods. For example, the commonly-used schema originally devised by Hardy 
(Hardy et al., 1991) also designates a pre-pro-B stage which discriminates precursors 
that have not commenced transcription of Ig-related genes, and lack expression of 
CD19 (see Figure 1.3.1). 
Developmental milestones from and inclusive of the pro-B-cell stage onwards 
are predominantly defined by the rearrangement status of the Ig heavy chain (Igh) and 
light chain (Igl) loci. The expression of recombination activating genes 1 and 2 (RAG1 
and RAG2), which generate the DNA strand breaks necessary for Ig gene 
rearrangement, is critical to this process (Oettinger et al., 1990; Schatz et al., 1989). 
Targeted knockout of either of these loci causes a complete absence of mature 
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lymphocytes in genetically-modified mice, with differentiation arrest at the pro-B-cell 
stage (Mombaerts et al., 1992; Shinkai et al., 1992). 
The RAG enzymes generate double-stranded DNA breaks that facilitate 
recombination of the Ig gene segments. Gene rearrangement is initiated with 
recombination of the diversity (DH) and joining (JH) regions of the Igh locus. 
Productive rearrangement of a variable (VH) region to the newly-formed DHJH 
segment results in synthesis of µ heavy chain (µH) protein, which forms part of the 
pre-B-cell receptor (pre-BCR). Successful recombination also leads to inhibition of 
recombination of the second IgH allele (allelic exclusion) (Schlissel, 2002). The 
structure of the pre-BCR is analogous to that of mature Ig: as the mature light chain 
binds µH to form mature Ig, so the surrogate light chain (SLC) binds µH to form the 
pre-BCR. The SLC is a heterodimer of VpreB1 (also known as CD179a) and λ5 
(mouse)/ λ14.1 (human) peptides (Sakaguchi and Melchers, 1986). Successful 
rearrangement of Igh and expression of the pre-BCR is a defining feature of 
progression to the large pre-B-cell stage, which is also characterised by expression of 
the CD25 antigen. 
Transition to the large pre-BII stage is accompanied by increased cellular 
proliferation, which is mediated by constitutive pre-BCR signalling. Following this 
phase of proliferative expansion, pre-BCR signalling causes downregulation of 
expression of λ5 and Vpreb1 in a negative feedback loop, inhibiting proliferation and 
causing cell cycle exit and differentiation to small pre-B cells (Martensson et al., 
2002). The role of Ikaros family proteins in the transition of pre-BCR proliferative 
function is discussed in Section 1.4.2. At the small pre-B-cell stage of development, 
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productive rearrangement of the Igl locus generates a functional light chain. The light-
chain associates with µH to form the B-cell receptor (BCR), which is expressed on the 
surface of immature B-cells. Following loss of CD25 and acquisition of IgD, CD21 
and CD22 expression, immature B-cells then exit the bone marrow to mature fully in 
the secondary lymphoid organs (Loder et al., 1999). 
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Figure 1.3.1 Schematic representation of B-cell development. Key surface antigen 
and transcript expression are listed in black, and Ig gene rearrangement status and 
expression of B-cell receptor (BCR) components are denoted in red. HSC, 
Haematopoietic Stem Cell. ELP, Early Lymphoid Progenitor. CLP, Common 
Lymphoid Progenitor. IgH, IgL Immunoglobulin Heavy and Light Chains. D, 
Diversity Segment. J, Joining Segment. V,
 
Variable Segment.  
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1.3.2 Transcriptional regulation of B-cell differentiation 
The complexity of the processes that underpin B-cell development mandates 
tight transcriptional regulation in order to ensure appropriate stage-specific gene 
expression. This control is provided by the coordinated action of a series of 
transcription factors (Nutt and Kee, 2007). Most of our knowledge regarding the 
function of specific transcription factors comes from observation of the phenotype of 
genetically modified mice with targeted knockdown of individual proteins. From this 
work, it is evident that PU.1, Bcl11a, E2a, Early B-cell factor 1 (Ebf1), Pax-5, Ikaros 
and Foxp1 all perform critical roles during normal B-lymphopoiesis. The roles of the 
latter two proteins will be discussed more fully in Sections 1.4 and 1.5, while relevant 
data from murine knockout models of the other transcription factors will be discussed 
in this section of the introduction. 
Similar phenotypes are seen with mice which lack PU.1, Bcl11a, E2a or Ebf1. 
Mice that have a deficiency of any of these factors all have blocks at very early stages 
of B-cell development. A mouse model in which the DNA-binding domain of PU.1 is 
disrupted has impairments in HSC homing, granulocyte/ monocyte and lymphocyte 
maturation and developmental arrest at the pro-B-cell stage (DeKoter et al., 2002). 
The defect in B-cell development can be specifically rescued by restoration of Ebf1 
expression, indicating that the primary role of PU.1 in pro-B-cells is the stimulation of 
Ebf1 transcription (Medina et al., 2004). Homozygous Bcl11a mutant mice also show 
a block in early B-cell development. Lymphoid-specific transcripts (including Ebf1, 
Pax5, and Cd19) are not detectable, and productive Igh rearrangement is absent, 
indicating a block at the pre-pro-B-cell stage (Liu et al., 2003). Targeted knockdown 
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of either E2a or Ebf1 results in similar phenotypes, as the murine lymphoid series 
shows developmental arrest prior to the onset of DHJH rearrangement (Bain et al., 
1994; Medina et al., 2004). E2a and Ebf1 proteins act together to promote 
transcription of many B-cell specific genes, including Pax-5, which is considered to 
be the master regulator of B-cell development (Medvedovic et al., 2011; Sigvardsson 
et al., 1997). Pax-5 null mice show arrest of B-cell development prior to any evidence 
of B-lymphoid commitment in the fetal liver (Urbanek et al., 1994), although the 
developmental block seen in post-natal mice occurs at a later (pro-B-cell) stage. Pax-5 
is critical for the maintenance of the B-cell state, mediating upregulation of B-cell 
specific genes (Nutt et al., 1998), and repression of non-lineage appropriate genes 
(Souabni et al., 2002). Conditional inactivation of Pax-5 in a mouse model resulted in 
re-expression of many Pax-5-repressed genes (Delogu et al., 2006). In a proportion of 
cells, this derepression led to de-differentiation to the pro-B-cell stage, and some of 
these cells can acquire T-cell differentiation capacity in vivo (Cobaleda et al., 2007). 
Of note, a subset of mice in which Pax-5 was conditionally inactivated developed 
leukaemia, while in humans, somatic deletion of PAX-5 is a common recurrent finding 
in childhood leukaemia (Mullighan et al., 2007).  
A growing body of evidence indicates that B-cell development is controlled by 
the interdependent action of multiple transcription factors in a series of positive and 
negative feedback networks. For example, Pax-5 is a direct transcriptional target of 
Ebf1, while Pax-5 in turn upregulates expression of Ebf1 (in company with many 
other B-cell-specific genes) in a positive feedback loop. In addition, Pax-5 inhibits 
expression of Notch-1, which is a repressor of Ebf1 (Reviewed in Mandel and 
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Grosschedl, 2012). Ebf1 expression is also regulated by E2a, and by Ebf1 protein 
itself (Roessler et al., 2007). It is increasingly clear that dissection of this factor 
interplay will be critical for the full elucidation of transcriptional regulation of B-
lymphopoiesis. 
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1.4 Ikaros 
The Ikaros family of transcription factors comprises three members (Ikaros, 
Aiolos and Helios) with predominantly haematopoietic expression (Molnar et al., 
1996; Schmitt et al., 2002) and the more widely-expressed Eos and Pegasus (Perdomo 
et al., 2000). The protein structure of all family members is characterised by the 
presence of two highly conserved Krüppel-type C2H2 zinc finger domains that 
mediate interaction with both DNA and other proteins. In Section 1.4.1, I will discuss 
how the structure of Ikaros (and its splice variants) contributes to protein function, 
cellular localisation and transcriptional activity. 
Ikaros was the founder member of the protein family, having initially been 
discovered to bind to regulatory elements of genes involved in lymphoid development, 
including Dntt and Cd3d (Georgopoulos et al., 1992; Lo et al., 1991). Transcripts are 
detected at the very earliest stages of extra-embryonic haematopoiesis (the Day 8 yolk 
sac), and levels of expression remain high in haematopoietic progenitors throughout 
fetal and adult life. Ikaros is present in erythroid and myeloid progenitors, but 
expression is greatly reduced following terminal differentiation of these cells. 
Conversely, the levels of Ikaros expression remain high throughout all stages of 
lymphoid development, including the most mature forms (Georgopoulos et al., 1997). 
This broad extent of expression at different stages of development in multiple cellular 
lineages suggests that Ikaros plays a key role in transcriptional regulation of normal 
haematopoetic differentiation (and lymphopoiesis in particular), and this hypothesis 
has been validated extensively in multiple murine models that are described in Section 
1.4.2. Despite a wealth of experimental data, the precise means by which Ikaros 
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proteins act to regulate gene expression during haematopoieis remains poorly 
understood, and this issue will also be explored in this section of the introduction. 
Importantly (in the context of this project), accumulating evidence supports the 
idea that Ikaros dysfunction is a key factor that contributes to poor treatment outcome 
in human leukaemia, and I will discuss these data in Section 1.4.3.  
 
1.4.1 Ikaros protein structure and isoforms  
 Ikaros is encoded by the Ikzf1 gene (Georgopoulos et al., 1994), which consists 
of seven highly conserved coding exons (John et al., 2009). As with all Ikaros family 
members, DNA-binding occurs via four central zinc fingers, while protein 
dimerisation (which is critical for full activity) is mediated by a C-terminal region 
containing two zinc fingers (Georgopoulos et al., 1992; Hahm et al., 1994). A 
schematic representation of Ikaros protein structure is shown in Figure 1.4.1. 
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Figure 1.4.1 Schematic representation of Ikaros protein structure. Black boxes 
represent zinc fingers, and blue boxes demarcate coding exons. The known functions 
of protein structural domains are indicated. 
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Alternative splicing of Ikzf1 pre-mRNA leads to expression of at least ten isoforms of 
Ikaros during normal lymphoid development (Mullighan et al., 2008), and the 
structure of some of these variants is depicted schematically in Figure 1.4.2. 
 
 
 
 
 
Figure 1.4.2 Schematic representation of Ikaros isoforms 1 – 6. All isoforms retain 
two C-terminal zinc fingers, but differ in the number of central DNA-binding zinc 
fingers, as indicated. 
40 
 
IK1 and IK2 are the isoforms that are expressed most abundantly in mature 
lymphocytes and lymphoid precursors, while IK4 levels are highest in immature 
thymocytes; all other isoforms are expressed at low levels in haematopoietic cells 
(Sun et al., 1996). The number of central zinc fingers varies between isoforms, and 
this confers differing DNA-binding properties. Importantly, splice variants which 
have fewer than two central zinc fingers do not bind DNA (Molnar and Georgopoulos, 
1994).  
All Ikaros isoforms retain the C-terminal domain, allowing dimerisation 
between different variants, and this may alter cellular localisation and transcriptional 
activity. Isoforms which normally exhibit predominantly cytoplasmic expression (i.e. 
all but IK1 and IK2, which are mainly nuclear) translocate to the nucleus following 
heterodimerisation with IK1 or IK2. Molecules which include DNA-binding isoforms 
exclusively (for example IK1/IK3 heterodimers) have equivalent transcriptional 
activity to IKI or IK2 homodimers. Critically, dimerisation of IK1 or IK2 with non-
DNA-binding isoforms (such as IK6, which lacks all four central zinc fingers) exerts a 
dominant negative effect, by sequestering DNA-binding proteins in complexes that 
cannot activate transcription (Sun et al., 1996). 
Other described structural regions include a bipartite activation domain, which 
is contained within the first 81 amino acids encoded by exon 7, upstream of the C-
terminal dimerisation region. This domain consists of two distinct acidic and 
hydrophobic regions, and is believed to mediate the interaction of Ikaros with the 
preinitiation complex, when Ikaros is bound to DNA (Georgopoulos et al., 1997). In 
addition, a 20 amino acid region located upstream of the central zinc fingers in Ikaros 
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isoform IK-H (which to date has been described to exist only in humans), appears to 
enhance chromatin binding of other isoforms following heterodimerisation with IK-H 
(Ronni et al., 2007). 
 
1.4.2 Ikaros function  
Experiments in genetically modified mice, which express Ikaros proteins that 
lack specific functional domains, have illustrated its critical role at multiple levels of 
haematopoietic development. Several of these murine models have been described, 
and I will discuss three key examples. 
The first model to be described involved a targeted deletion of Ikzf1 exons 3 
and 4 (which encode three central zinc fingers), that results in expression of a non-
DNA-binding dominant negative protein (IkarosDN). These mice have a complete 
block in lymphoid development, involving T-, B- and Natural Killer (NK) cells and 
their respective progenitors, including the very earliest forms (Georgopoulos et al., 
1994). Mice that are heterozygous for the same deletion develop acute T-cell 
leukaemia/ lymphoma, which is fatal at an early age. Of note, T-lymphocytes isolated 
from pre-leukaemic animals are hyperproliferative in vitro, while progression to overt 
leukaemia is associated with somatic loss of the remaining wild-type Ikzf1 allele 
(Winandy et al., 1995). 
Deletion of the C-terminal dimerisation domain (which causes protein 
instability and results in effective absence of Ikaros expression) causes a complete 
block in fetal and adult B-lymphopoiesis, and fetal T-lymphopoiesis. These mice do 
however have normal total numbers of T-lymphocytes in adult life, although with 
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abnormal distribution of T-cell subsets (including a skew towards CD4+CD8- 
expression and a gross reduction in thymic dendritic antigen presenting cells). These 
mice also demonstrate hyperproliferative T-cell receptor responses in vitro (Wang et 
al., 1996). 
Myeloid and erythroid development are largely uncompromised in these two 
mouse models, however a strain (Plastic) in which a point mutation disrupts DNA-
binding has severe defects in fetal erythropoietic differentiation, which is fatal in utero 
(Papathanasiou et al., 2003). These mice have also subsequently been shown to have 
defective self-renewal of the long-term reconstituting haematopoietic stem cell (HSC) 
compartment (Papathanasiou et al., 2009). 
Although these critical roles for Ikaros in haematopoiesis are well-established, 
the precise mechanisms by which its transcriptional effects are exerted remain poorly 
elucidated.  Few direct targets of Ikaros have been described, though these include 
several genes that are critical for lymphopoiesis such as Dntt (Georgopoulos et al., 
1992), Rag (Yannoutsos et al., 2004) and Igll1, which encodes the λ5 component of 
the surrogate light chain expressed at the large pre-B-cell stage of development 
(Sabbattini et al., 2001). In addition, Ikaros has been shown to negatively regulate the 
G1/S phase transition of the cell cycle of pre-B lymphocytes. This effect has been 
shown to be mediated by binding of Ikaros to the c-myc promoter, which results in 
gene silencing and subsequent inhibition of cellular proliferation that is necessary for 
progression to the small pre-B-cell stage (Ma et al., 2010). 
Ikaros has been shown to be involved in both activation and repression of 
genes in vivo and in transfection assays (Harker et al., 2002; Molnar and 
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Georgopoulos, 1994; Sabbattini et al., 2001; Sun et al., 1996). This divergent activity 
even extends to individual genetic elements, as Ikaros can either activate or repress 
transcription of the upstream regulatory element of Sfpi1 (which encodes PU.1), 
depending on cellular context (Zarnegar and Rothenberg, 2011). The repressive 
effects of Ikaros have been suggested to be mediated by interaction with chromatin 
modifiers, as physical interactions with the Mi-2/nucleosome remodeling and 
deacetylase (NuRD) complex (Kim et al., 1999) and the PYR complex (O'Neill et al., 
2000) have been demonstrated. In addition, Ikaros has been shown to co-localise with 
silent genes at transcriptionally inactive pericentric heterochromatin (Brown et al., 
1997), although the mechanistic relevance of this finding remains uncertain, as known 
transcriptional activators (such as C/EBP) have been shown to exhibit similar 
distribution (Tang et al., 1999). An additional factor that probably contributes to 
transcriptional repression in vivo is the observed overlap of Ikaros binding sites with 
those of transcriptional activators. For example, Ikaros occupancy of the Dntt 
promoter blocks binding of the transcriptional activator Ets1 at the same location, and 
disruption of Ikaros binding by mutagenesis of this locus prevents downregulation of 
Dntt promoter activity in stable transfection assays (Trinh et al., 2001). 
A further level of complexity is provided by the fact that Ikaros family proteins 
can combine to regulate gene expression in a developmental stage-specific manner. 
This is exemplified by the regulation of Igll1 expression during B-lymphopoiesis. At 
the large pre-B-cell stage, the extent of Igll1 expression is governed by the relative 
ratios of Ikaros (repressive) and Ebf1 (activating) proteins. Exit from this stage of 
development is dependent on binding of the Ikaros family member Aiolos to the Igll1 
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promoter, which results in transcriptional silencing, exit from the cell cycle and 
transition to the small pre-B-cell stage (Thompson et al., 2007).  
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1.4.3 Ikaros dysfunction in human leukaemia 
Evidence from the aforementioned murine models confirmed Ikaros as a 
lymphoid tumour suppressor in mice. Reports of Ikaros dysfunction in human 
leukaemia were initially confined to reports of several small case series, that identified 
aberrant Ikaros isoform expression in subsets of human B-ALL (Nakase et al., 2000; 
Ruiz et al., 2004) and acute myeloid leukaemia (Yagi et al., 2002). These cases were 
found to overexpress the non-DNA-binding dominant negative isoform IK6, and this 
was originally thought to occur as a result of abnormal RNA splicing. More recent 
work (predominantly from genome-wide analysis of primary human ALL samples 
using single nucleotide polymorphism (SNP) arrays) has however shown that IK6 
expression predominantly occurs as a result of genomic deletions of IKZF1. These 
highly important findings (which have critical implications for the results detailed in 
this thesis) will be discussed in depth in Section 1.6.2. 
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1.5 Forkhead Box Protein P1 (Foxp1) 
Forkhead box (Fox) proteins are a family of evolutionarily conserved 
transcription factors which are characterised by a 110 amino acid forkhead (also 
known as ‘winged helix’) region which mediates DNA binding (Carlsson and 
Mahlapuu, 2002). This domain was originally defined by homology with the protein 
product of the Drosophila forkhead gene (Weigel and Jackle, 1989), and consists of 
three alpha helices, three beta sheets and two loops or turns which form a HLH-like 
motif. DNA binding is believed to occur primarily through the third alpha helix (to the 
DNA major groove) and the second wing (to the DNA minor groove) (Clark et al., 
1993). 
The Fox protein family currently comprises 19 subfamilies (A to S), which are 
categorised by the position of certain conserved amino acids in the forkhead domain 
(Wijchers et al., 2006). Fox proteins perform key functions in a diverse range of 
cellular processes, including metabolism, differentiation, proliferation and apoptosis 
(Myatt and Lam, 2007). The four members of the Foxp subfamily (Foxp1-4) play 
essential roles in development and immunity in mammals (Santos et al., 2011). 
Forkhead box protein P1 (Foxp1 in mice, FOXP1 in humans) was the first member of 
the subfamily to be identified, having been cloned from a mouse B-cell leukaemia line 
(Lai et al., 1993). It is widely expressed in mammalian tissues (with highest levels in 
lymphocytes, neural tissue and gut) and is a critical transcriptional regulator during B-
lymphopoiesis (Banham et al., 2001; Shu et al., 2001; Wang et al., 2003). The other 
FoxP subfamily members have primary roles in central nervous system development 
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(Foxp2), Regulatory T-lymphocyte function (Foxp3) and pulmonary and gut 
development (Foxp4) (Lu et al., 2002; Shu et al., 2007; Yagi et al., 2004). 
In this part of the introduction, I will describe how the structure of Foxp1 and 
its splice variants contributes to protein function (Section 1.5.1). I will then discuss 
the experimental evidence that has revealed a critical role for Foxp1 in 
haematopoiesis, and the potential means by which its transcriptional effects are 
exerted (Section 1.5.2). In Section 1.5.3, I will review the increasing body of data 
which implicates FOXP1 in the pathogenesis of human lymphoid malignancy. 
 
1.5.1 Foxp1 protein structure and isoforms 
The Foxp1 gene consists of 16 coding exons, and several structural domains 
have been described. A schematic representation of Foxp1 protein structure is shown 
in Figure 1.5.1.  
 
 
Figure 1.5.1 Schematic representation of Foxp1 protein structure. Boxes 
demarcate defined protein structural regions (described in the lower portion of the 
figure). The known functions of the indicated domains are listed in the upper part of 
the figure. 
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In common with other members of the Foxp subfamily, Foxp1 exhibits 
truncation of the forkhead region at the helices of the first two ‘wings’ of the domain 
(Chatila et al., 2000). Several isoforms of the protein are expressed (at least 11 in 
mice, and at least 9 in humans). The relative distribution of these isoforms varies 
according to cell type, and this may contribute to tissue-specific transcriptional 
activity. For example, a Foxp1 splice variant which is expressed specifically in murine 
embryonic stem (ES) cells preferentially stimulates the transcription of genes required 
for ES cell pluripotency (Gabut et al., 2011). A schematic representation of the 
structure of some Foxp1 splice variants is shown in Figure 1.5.2. 
 
 
 
Figure 1.5.2. Schematic representation of Foxp1 splice variants. Foxp1A is the 
predominant Foxp1 isoform expressed during normal lymphoid development. Foxp1C 
and Foxp1D (which are expressed following B-cell activation) lack one or both of the 
polyglutamine and glutamine-rich regions which are important for modulation of 
Foxp1 transcriptional activity. 
49 
 
All Foxp1 isoforms contain leucine zipper and zinc finger motifs that mediate 
protein dimerisation, which in turn is necessary for efficient DNA binding (Wang et 
al., 2003). The longest isoforms (Foxp 1A and Foxp1B in mice) include an N-terminal 
polyglutamine region which is involved in modulation of transcriptional repressive 
activity (Wang et al., 2003). The structure of the C-terminal acidic region predicts a 
role in protein transactivation (Banham et al., 2001). Patterns of Foxp1 isoform 
expression also appear to vary during normal B-cell development. For example, 
cellular levels of shorter isoforms which lack the polyglutamine region (Foxp1C and 
Foxp1D in mice, isoforms 3 and 9 in humans) increase following B-cell activation 
(Brown et al., 2008). 
 
1.5.2 Functions of Foxp1  
In murine models, homozygous deletion of Foxp1 is lethal in utero due to heart 
valve and cardiac outflow tract defects (Shu et al., 2001; Wang et al., 2004). 
Reconstitution experiments using fetal liver haematopoetic precursor cells (HPCs) 
from Foxp1-null mice subsequently revealed a critical role for Foxp1 in B-
lymphopoiesis. Following sublethal irradiation and reconstitution with Foxp1-null 
HPCs, recipient mice had an arrest of B-lymphopoiesis at the transition from the pro- 
to large pre-B-cell stages. This developmental block was associated with decreased 
expression of recombination activating genes 1 and 2 (Rag1 and Rag2), which are 
required for immunoglobulin gene recombination and progression to the large pre-B-
cell stage. Decreased Rag expression was shown to be linked to a loss of binding of 
Foxp1 to the B-cell specific Erag enhancer (Hu et al., 2006). 
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Experimental evidence implicates Foxp1 in the regulation of cell turnover, with 
effects that appear to be tissue-specific. For example, Foxp1 has been shown to be 
essential for the generation and maintenance of quiescence in T-lymphocytes. 
Conditional deletion of Foxp1 at the CD4+ CD8+ double positive (DP) stage of 
thymocyte development resulted in premature T-cell activation and acquisition of 
effector function in a mouse model (Feng et al., 2010). Recently, this effect was 
shown to be mediated by transcriptional repression of the IL-7 receptor α-chain gene 
(IL7rα) by Foxp1, which competes with Foxo1 (a transcriptional activator) for binding 
to a forkhead recognition site in the IL7rα locus (Feng et al., 2011). Foxp1 has also 
been shown to inhibit proliferation in developing murine cardiomyocytes by 
repressing Nkx2.5 transcription (Zhang et al., 2010). Conversely, Foxp1 has been 
described to stimulate B-lymphocyte proliferation through an interaction with 
microRNA-34a (miR-34a). Overexpression of miR-34a was shown to block 
lymphocyte development, resulting in a similar phenotype to that seen with Foxp1 
null mice. This effect was shown to be mediated through direct inhibition of Foxp1 
expression by mir-34a, while targeted knockdown of miR-34a in a murine model 
resulted in increased Foxp1 protein expression and increased numbers of mature B-
cells (Rao et al., 2010).  
Little investigation of the mechanism of Foxp1-mediated transcriptional 
repression has been reported. Several groups have described physical interaction of 
Foxp1 with transcriptional repressor complexes. For example, Foxp1 has been shown 
to recruit the corepressor protein C-terminal binding protein 1 (CtBP-1) (Li et al., 
2004), and to associate with the SMRT nuclear corepressor at the promoter of the p21 
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gene (Jepsen et al., 2008). Foxp1 (in addition to Foxp2 and Foxp4) was also shown to 
interact directly with the p66β component of the NuRD complex, and to repress gene 
transcription by a mechanism requiring histone deacetylation by the enzymes histone 
deacetylase 1 and 2 (HDAC1 and HDAC2) (Chokas et al., 2010). 
 
1.5.3 FOXP1 dysfunction in human lymphoid malignancy 
Deregulated expression of several subfamilies of FOX proteins is observed in a 
wide range of neoplasia (Reviewed in Myatt and Lam, 2007). FOXP1 was initially 
considered to be a tumour suppressor in humans, as it is located in a chromosomal 
region (3p14.1) which exhibits loss of heterozygosity in several human malignancies. 
FOXP1 mRNA expression was found to be diminished (compared with the normal 
tissue equivalent) in many epithelial carcinomas (Banham et al., 2001), while reduced 
levels of nuclear FOXP1 were described to be associated with a poor prognosis in 
breast cancer patients (Fox et al., 2004). 
More recent evidence however suggests an opposing (i.e. oncogenic) role for 
FOXP1 in the context of lymphoid malignancies. Recurrent translocation of FOXP1 
(predominantly involving the IGH locus as a translocation partner) was described in 
several subtypes of non-Hodgkin’s lymphoma (NHL), including Mucosa-Associated 
Lymphoid Tissue (MALT) Lymphoma (Streubel et al., 2005), and Diffuse Large B-
Cell Lymphoma (DLBCL) (Wlodarska et al., 2005). Subsequently, increased 
expression of shorter FOXP1 isoforms (isoforms 3 and 9, which are analogous to 
murine Foxp1C and Foxp1D) have been strongly linked to a poor prognosis in the 
activated B-cell subtype of DLBCL (Brown et al., 2008). FOXP1 has now also been 
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reported as a recurrent (although rare, with only five reported cases) translocation 
partner of PAX-5 in both adult and childhood B-ALL (Coyaud et al., 2010; Mullighan 
et al., 2007; Put et al., 2011). Taken together, these data suggest that deregulation of 
FOXP1 activity frequently contributes to transcriptional dysfunction in human 
lymphoid malignancy. 
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1.6 B-cell Acute Lymphoblastic Leukaemia 
Leukaemia (literally ‘white blood’, from the Greek) comprises a range of 
disorders of leukocyte proliferation and differentiation, characterised by the 
accumulation of malignant white blood cells and compromise of residual bone 
marrow function that results in life-threatening susceptibility to infection and bleeding 
(Pui, 1996). At the broadest level, leukaemias are classified by lymphoid or myeloid 
origin. ‘Acute’ leukaemia refers to the rapid proliferation of developmentally-arrested 
immature progenitors (blasts), while ‘chronic’ leukaemia involves the accumulation of 
more differentiated cells. In this section of the introduction, I will review the current 
knowledge of the biology of B-lymphoid acute lymphoblastic leukaemia (ALL). 
Although ALL is an uncommon disease, with 600-700 cases per year in this 
country (UK Office for National Statistics), its clinical importance relates to its 
relatively high incidence in young people, and poor prognosis in older patients. ALL 
is the commonest malignancy and the leading cause of non-traumatic death in children 
and young adults (Advani et al., 2009), despite treatment advances in recent decades. 
Children diagnosed with leukaemia in the UK currently have at least an 80% chance 
of long-term cure overall, and survival rates exceed 90% in some cytogenetic 
subgroups (Bhojwani et al., 2011; Pui and Evans, 2006). The outlook for adult 
patients is dismal by comparison, with corresponding rates of treatment success of 
approximately 40% (Pui et al., 2008). In the main, this reflects a higher relative 
incidence of leukaemia-associated genetic aberrations associated with poor outcome 
(discussed in Sections 1.6.1 and 1.6.2), and a poorer tolerance of treatment-related 
side-effects. 
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Modern categorisation of haematological malignancy (as typified by the 
current World Health Organisation (WHO) proposed classification system) relies on a 
combination of cellular morphology, immunophenotype and genetic analysis to 
discriminate disease subtypes. In the WHO classification system, the 
immunophenotype of precursor B-ALL corresponds to that of lymphoid progenitors 
up to and including the immature B-cell stage. Logically, leukaemic blasts may be 
considered to be the malignant counterparts of haematopoietic precursors in which 
normal developmental processes have been subverted by acquired genetic anomaly. 
Investigation of the downstream molecular effects of these genetic aberrations is 
therefore critical for understanding the biology of the disease. In this section of the 
introduction, I will discuss how some of the abnormalities that are most commonly 
seen in ALL contribute to lymphoid differentiation arrest. The latter part of this 
section will focus specifically on Philadelphia-positive ALL (that is characterised by 
the presence of BCR-ABL translocation), as deletions in IKZF1 that typify these cases 
have direct relevance for the experimental results of this project.  
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1.6.1 Genetic abnormalities in B-ALL 
The incidence of recurrent structural chromosomal abnormalities that are seen in 
childhood and adult B-ALL is depicted in Figure 1.6.1. The vast majority of these 
involve numerical anomalies (predominantly hyperdiploidy), or translocations that 
result in aberrant expression or regulation of transcription factors, tyrosine kinases or 
proto-oncogenes. It is likely that there is much overlap in the downstream effects of 
these genetic events, and it is evident that blast cell accumulation results from 
alterations in molecular pathways involved in cellular self-renewal, proliferation, 
differentiation, or apoptosis (Hanahan and Weinberg, 2000). For example, leukaemias 
which harbour diverse fusion transcription factors frequently exhibit similar activation 
of homeobox (HOX) genes, which are important for cellular differentiation and 
proliferation (Buske and Humphries, 2000). 
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Figure 1.6.1 The incidence of recurrent structural chromosomal abnormalities in 
childhood and adult ALL. Modified with permission from Pui et al, N Engl J Med 
350; 15: 1535-48, Copyright Massachusetts Medical Society. 
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It is instructive to consider the mechanism by which transcription factor fusion 
genes contribute to leukaemogenesis, via subversion of normal protein function. The 
genes involved typically encode transcription factors that are developmentally 
regulated and affect cellular differentiation (Armstrong and Look, 2005). A cardinal 
example is the ETV6-RUNX1 (formerly TEL-AML1) fusion gene that results from the 
t(12;21) (p13;q22) translocation (Speck and Gilliland, 2002). RUNX1 normally acts 
as a transcriptional activator, and is critical for normal haematopoiesis (Ichikawa et 
al., 2004). Fusion to ETV6 (a gene that is also essential for haematopoiesis) induces 
aberrant recruitment of histone deacetylases, thereby converting RUNX1 into a 
transcriptional repressor (Downing, 2003). Profiling studies have shown that 
leukaemias that harbour ETV6-RUNX1 translocations have highly similar gene 
expression patterns, indicating a common mechanism of leukaemogenesis through 
transcriptional dysregulation that is caused by the fusion protein (Yeoh et al., 2002). 
Recent advances in the speed and resolution of profiling technology have 
allowed comprehensive assessment of genetic alterations in leukaemic cells, thereby 
revolutionising our understanding of the ALL genome. The vast majority of data 
generated from these studies have come from analysis of childhood ALL cases using 
single nucleotide polymorphism (SNP) arrays (Mullighan, 2011). The key finding 
from these studies has been the identification of recurrent anomalies (deletions, 
mutations and translocations, that are mostly heterozygous) in genes that encode 
transcriptional factors which are critical for B-cell development, including PAX5, 
EBF1 and IKZF1 (Kawamata et al., 2008; Kuiper et al., 2007; Mullighan et al., 2007). 
The significance of the IKZF1 deletion is discussed in detail in Section 1.6.2.1. Over 
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two thirds of cases of childhood B-ALL have alterations that are predicted to disrupt 
differentiation at early stages of lymphoid commitment (see Section 1.3), which is 
consistent with the most commonly observed leukaemic immunophenotype of pro-B-
cell developmental arrest. 
These studies have also identified several additional recurrent lesions that are 
likely to contribute to leukaemogenesis, and treatment response. Deletions involving 
genes that encode tumour suppressor and cell cycle regulatory proteins (CDKN2A/B, 
PTEN and RB1), lymphoid signalling factors (CD200, BTLA, BLNK) and molecules 
involved in drug response (NR3C1) have all been described. An additional important 
finding was that the number of additional (and presumably cooperative) lesions varies 
markedly with cytogenetic subtype. For example, the incidence of additional genetic 
lesions in Mixed Lineage Leukaemia gene (MLL)-rearranged leukaemia is low, 
indicating that MLL rearrangement in itself may be sufficient to induce leukaemia 
(Bardini et al., 2010). In contrast, ETV6-RUNXI+ leukaemias typically contain 
multiple additional abnormalities (Mullighan et al., 2007). 
 
 
1.6.2 Philadelphia-positive (BCR-ABL+) ALL 
The discovery of the Philadelphia (Ph) chromosome in 1960 (by Peter Nowell 
and David Hungerford, who carried out their research in Philadelphia) was a seminal 
moment in cancer genetics, as it constituted the first description of a leukaemic fusion 
oncogene. This derivative chromosome 22 results from the t(9;22) (q34;q11) 
translocation which causes juxtaposition of  the ABL gene on chromosome 9 with the 
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breakpoint cluster region (BCR) on chromosome 22. The translocation is depicted 
schematically in Figure 1.5.2. The resultant fusion gene encodes the oncogenic BCR-
ABL tyrosine kinase. 
The Ph chromosome is found in the vast majority (at least 95%) of cases of 
chronic myeloid leukaemia (CML), and 25% of adult ALL (it is much less common in 
childhood ALL, comprising 3-5% of cases) (Pui, 1996). The location of breakpoint 
cluster region (BCR) breakpoints varies between CML and ALL, and the fusion 
proteins are either 210kDa (p210) or 190kDa (p190) respectively (Clark et al., 1987). 
Tyrosine kinase activity is well-characterised (Van Etten et al., 1989), but the 
precise function of the normal product of the ABL gene is not known, although it 
appears to play a role in DNA damage response (Kharbanda et al., 1995).  Fusion to 
BCR elements results in increased kinase activity, aberrant cytoplasmic localisation 
(Lugo et al., 1990), and activation of multiple pro-proliferative pathways, including 
RAS/ MAPK and JAK/STAT (Van Etten, 2002).  
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Figure 1.6.2 The Philadelphia Chromosome. The ABL and BCR genes are located 
on chromosomes 9 and 22, respectively. The t(9;22) translocation results in the 
formation of the BCR-ABL fusion gene in the derivative chromsome 22 (the 
Philadelphia chromosome). Adapted by permission from Macmillan Publishers Ltd 
(Lydon, Nature Medicine 15, 1153-7), copyright 2009. 
 
BCR-ABL+ ALL has traditionally been associated with a dismal long-term 
prognosis (Fletcher et al., 1991). The development of targeted tyrosine kinase 
inhibition with imatinib has provided recent hope of improved cure rates, and early 
outcome data indicates that addition of this agent to intensive paediatric-based 
treatment protocols may improve survival appreciably (Hunger, 2011). The precise 
mechanism by which BCR-ABL positivity contributes to adverse outcome is unclear. 
In children, BCR-ABL+ ALL is associated with adverse prognostic features such as 
high leukocyte count at diagnosis and an increased incidence of central nervous 
system involvement (Crist et al., 1990). In addition, BCR-ABL has been shown to 
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exert an anti-apoptotic effect via upregulation of Bcl-xL (Skorski, 2002), that is likely 
to contribute to enhanced cellular survival and chemotherapeutic resistance in vivo. 
High-resolution characterisation of the BCR-ABL+ ALL genome has now revealed 
that IKZF1 deletion is the key event that is associated with poor outcome in this 
disease.  
 
1.6.2.1 BCR-ABL+ ALL and IKZF1 deletion 
SNP microarray profiling has shown that IKZF1 deletions occur in at least 84% 
of cases of BCR-ABL+ ALL (Iacobucci et al., 2009; Mullighan et al., 2008). 
Approximately half of these heterozygous anomalies involve deletion of exons 3-6, 
and result in expression of the dominant negative IK6 isoform (discussed in Section 
1.4.1). The presence of these deletions is associated with an adverse prognosis within 
the BCR-ABL+ ALL cohort (Martinelli et al., 2009), and were subsequently also 
found to be associated with poor outcome (with up to three-fold increased risk of 
relapse) in BCR-ABL negative (BCR-ABL-) ALL (Kuiper et al., 2010; Mullighan et 
al., 2009b; Yang et al., 2011). Intriguingly, these cases exhibit gene expression 
profiles that are very similar to IKZF1-deleted BCR-ABL+ ALL. Increased expression 
of stem cell-associated genes (e.g. MPL) and reduced expression of B-cell signalling 
genes (e.g. CD19) suggests that IKZF1 deletion contributes directly to differentiation 
arrest in these cases (Mullighan and Downing, 2008). It is notable that IKZF1-deleted 
BCR-ABL- cases commonly have additional alterations in genes coding for cytokine 
receptors (e.g. CRLF2) and tyrosine kinases (including Janus-associated kinases 1-3) 
(Harvey et al., 2010; Mullighan et al., 2009a). Mechanistically, this suggests that 
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molecular targets of BCR-ABL are also activated by dysregulation of these pathways, 
although this has not been proved experimentally as of yet. 
Further evidence of a key role for Ikaros dysfunction in human leukaemia is 
provided by several additional reports. Forced expression of IK6 in human umbilical 
cord stem cells has been shown to cause impairment of B-lymphoid maturation in 
vitro (Tonnelle et al., 2001; Tonnelle et al., 2009). In addition, data from genome-
wide association studies of several patient cohorts indicates that germline 
polymorphism of IKZF1 is associated with an increased lifetime risk of ALL 
development (Papaemmanuil et al., 2009; Prasad et al., 2010; Trevino et al., 2009) 
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1.7 Aim of the Project 
 As detailed so far, successful B-lymphopoiesis depends upon the actions of a 
series of interdependent transcription factors that regulate developmental gene 
expression. The subversion of these processes results in B-ALL, as exemplified by 
common recurrent genetic abnormalities that directly inhibit normal transcription 
factor function (ETV6-RUNX1), and that have been shown to contribute directly to 
differentiation arrest (IKZF1 deletion). 
The aim of this project was to study the interaction between two factors that are 
critical for B-lymphopoiesis (namely Ikaros and Foxp1), and to elucidate the 
functional importance of this interaction in normal B-cell development and B-ALL. 
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Chapter 2 
Materials and Methods 
2.1 Cell cultures 
 All cells were grown at 370C with 5% atmospheric CO2. 
2.1.1 Human Embryonic Kidney (HEK) 293T cells 
293T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 
10% fetal calf serum (FCS) (volume/volume) and L-Glutamine (2mM). 
2.1.2 B3 cells 
B3 cells were originally derived from a lymphoma, which was isolated from a 
transgenic mouse that expressed the IL-7 gene under the control of the Eα (MHC 
class II) promoter (Fisher et al., 1995). Cells were maintained in Iscove’s Modified 
Dulbecco’s Medium (IMDM) supplemented with 10% FCS, L-Glutamine (2mM), β-
mercaptoethanol (50µM) and IL-7 (2ng/ml). 
2.1.3 Acute Lymphoblastic Leukaemia cell lines 
The REH cell line was purchased from Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMZ). The SUP-B15 line was a gift from Dr. 
Owen Williams and Dr. Jasper de Boer (Institute of Child Health, University College 
London). Both cell lines were grown in RPMI with 20% FCS and L-Glutamine 
(2mM). 
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2.2 Plasmid constructs 
2.2.1 Expression vectors used for 293T cell transfection 
Modified PCDNA expression vectors containing two FLAG epitopes (PDF-
DNAIII) or a HA epitope (PCDNA3.1-HA) were gifts from the Lymphocyte 
Development Group, MRC Clinical Sciences Centre. Vector maps are shown in 
Figure 2.1. A high-fidelity DNA polymerase (PFU Turbo, Stratagene) was used for all 
PCR amplifications. 
The cDNAs that encode murine WT and mutant Ikaros proteins were amplified 
by PCR from the corresponding retroviral plasmid (Section 2.2.3) and inserted 
between the XhoI and XbaI restriction sites of the PCDNA3.1-HA vector (Figure 2.1). 
The corresponding human constructs were amplified by PCR from cDNA isolated 
from the REH cell line. The cloning of human IK6 cDNA involved a two step process. 
5’ (corresponding to IKZF1 exons 1 and 2) and 3’ (corresponding to IKZF1 exon7) 
fragments were amplified separately. Amplification products had complementary 
sequences which allowed annealing of the 3’end of the exon 1/2 fragment to the 5’ 
end of the exon 7 fragment. The fragments were annealed and amplified again in order 
to generate the complete IK6 cDNA. The integrity of all constructs generated by PCR 
was confirmed by sequencing of the inserts. 
The cDNAs of murine WT and mutant Foxp1 proteins were either amplified 
from a retroviral plasmid or purchased commercially (GeneCust, Luxembourg or Blue 
Heron Biotechnology, Washington, USA) and were cloned between the BamHI and 
XhoI restriction sites of the PDF-DNAIII vector (Figure 2.1). Human FOXP1 cDNA 
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was amplified by PCR from the REH cell line, and was inserted between the BamHI 
and XhoI restriction sites of the PDF-DNAIII vector. 
2.2.2 Expression vectors used in generation of GST-tagged proteins 
cDNA fragments were obtained either by PCR amplification or digestion of the 
corresponding PCDNA plasmid (Section 2.2.1) and were inserted between the BamHI 
and XhoI restriction sites of the  pGEX-4T vector (GE Healthcare and vector map 
shown in Figure 2.1). 
2.2.3 Retroviral vectors used for B3 cell infection 
Retroviral vectors were derived from the pMSCV-IRES-GFP (pMIG) plasmid, 
and cDNAs were inserted between the BglII and XhoI restriction sites (Figure 2.1). 
The pMIG-Ikaros-HA construct was generated by the Lymphocyte Development 
Group, MRC Clinical Sciences Centre. The pMIG-FLAG-Foxp1 plasmid was 
generated following amplification of Foxp1 cDNA from the PDF-DNAIII-Foxp1 
vector, while the cDNA of murine IK6 was synthesised commercially (GeneCust, 
Luxembourg).  
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Figure 2.1 Maps of Expression Vectors used in transfection and infection 
experiments. A. PDF-DNAIII. B. PCDNA3.1-HA. C. PGEX-4T-1. D. PMSCV-
IRES-GFP. The locations of restriction enzyme recognition sequences in the multiple 
cloning site are shown. 
C
D
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2.3 Transfection of HEK 293T cells 
293T cells were transfected using the calcium phosphate method (Nature 
Methods, 2005). Briefly, HEPES Buffered Saline (pH 7.05) was added to a solution 
containing 4µg of plasmid DNA in the presence of 2.5M CaCl2 and incubated for 5 
minutes at room temperature. For co-transfections, 4µg of each plasmid were added. 
The mixture was then added to HEK 293T cells cultured on a 10cm plate at 
approximately 50% confluence. The transfection mix was replaced with fresh 293T 
culture medium 24 hours later, and protein lysates were extracted 48 hours after 
transfection (see Section 2.4). 
 
2.4 Preparation of protein extracts 
All lysis buffers were supplemented with Complete Mini, EDTA-free Protease 
Inhibitor (Roche). Following extraction, the concentration of protein extracts was 
determined using the Bradford method (Bradford, 1976), after which the lysate was 
snap frozen in liquid nitrogen then stored at -800C until required. 
2.4.1 Whole cell extracts 
In order to prepare whole cell extracts, approximately 107 cells were washed 
once with phosphate buffered saline (PBS), and the cell pellet was suspended in lysis 
buffer (40mM Tris pH 8.0, 200mM NaCl, 0.1% NP40, 40mM NaF, 2mM NaVO3, 
200µM DTT, 20% Glycerol and bovine serum albumen (BSA) 1µg/ml). The solution 
was snap frozen in liquid nitrogen and then subjected to three consecutive freeze-thaw 
cycles. Extracts were recovered from the supernatant following centrifugation at 
10,000 x g at 40C for 10 minutes. 
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2.4.2 Nuclear extracts 
Nuclear extracts were prepared by a two-stage method. Approximately 107 
cells were washed once in PBS. The cell pellet was initially resuspended in a low 
osmolarity buffer (10mM HEPES pH 7.9, 10mM KCl, 0.1mM EDTA and 0.1mM 
EGTA) and allowed to swell on ice for 15 minutes, in order to lyse the cell outer 
membranes. After addition of NP40 (to a concentration of 0.6%), the solution was 
mixed vigorously by vortexing, and subjected to centrifugation at 10,000 x g at 40C 
for 30 seconds. The nuclear pellet was recovered and resuspended in a high osmolarity 
nuclear lysis buffer (20mM HEPES pH 7.9, 400mM NaCl, 1mM EDTA and 1mM 
EGTA) and incubated with shaking at 40C for 30 minutes. Nuclear extracts were 
recovered in the supernatant following centrifugation at 10,000 x g at 40C for 5 
minutes.  
 
2.5 Reagents used for protein co-immunoprecipitation and 
immunoblotting.  
2.5.1 Primary antibodies. 
The following primary antibodies were used for both protein co-
immunoprecipitation (co-IP) and immunoblotting: monoclonal anti-FLAG M2 
(Sigma-Aldrich), monoclonal anti-HA (Covance), monoclonal anti-Foxp1 (Abcam), 
polyclonal anti-Ikaros (generated by the Lymphocyte Development Group, MRC 
Clinical Sciences Centre). Normal mouse IgG and normal rabbit IgG (both Santa Cruz 
Biotechnologies) were used as controls for non-specific antibody precipitation during 
protein co-IP (Section 2.6). 
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2.5.2 Secondary antibodies used for immunoblotting. 
Goat anti-mouse and goat anti-rabbit horseradish peroxidase-conjugated 
antibodies (both Santa Cruz Biotechnologies) were used as secondary antibodies for 
immunoblotting. 
2.5.3 Western blotting 
Protein extracts were resolved by polycrylamide gel electrophoresis, then 
transferred to polyvinylidene fluoride membranes and probed with the relevant 
antibodies. The membranes were developed with Western Lightning Plus ECL 
chemiluminescence reagent (PerkinElmer) and exposed to Amersham Hyperfilm ECL 
(GE Healthcare). 
For quantification of proteins according to band intensity, the membrane was 
developed with ECL reagent and a digital image was taken using an ImageQuant LAS 
4000 Mini machine (GE Healthcare). The image was exported to ImageQuant 
software (Fuji) and band intensity was quantified and normalised to a protein loading 
control (β-tubulin). 
 
2.6 Protein co-immunoprecipitation (co-IP) 
0.5 µg of antibody was coupled to 50µl of Protein G Dynabeads (Sigma-
Aldrich) by incubation with rotation at room temperature for 10 minutes. The beads 
were washed with buffer (0.1M Na2HPO4, pH 8.0) to remove unbound antibody from 
the solution. Protein extracts were then incubated with the antibody-coupled beads for 
30 minutes at room temperature, after which the beads were washed three times with 
PBS using the magnetic separator. In selected experiments, protein lysates were 
72 
 
subjected to treatment with either DNase (Roche) or ethidium bromide according to 
previously described protocols (Lai and Herr, 1992) prior to IP, in order to abolish 
DNA-protein interactions. 
Immunocomplexes were eluted by boiling the beads in 1x NuPAGE LDS 
Sample Buffer (Invitrogen) for 10 minutes at 700C with shaking. Eluates were 
resolved by SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene 
fluoride membranes and probed with the relevant antibodies. 5% of the lysate amount 
that was used for IP was loaded on the same polyacrylamide gel, in order to provide 
an ‘input’ comparison.  
 
2.7 GST pulldown assays 
2.7.1 Preparation of GST fusion proteins 
BL21-CodonPlus Competent Cells (Promega) were transformed (according to 
the manufacturer’s protocols) with pGEX-4T plasmids that contain the relevant 
cDNA. Several bacterial strains (RPL, RIL and RP) were used, and these had similar 
levels of ultimate protein recovery. Gene expression was stimulated by addition of 
Isopropyl β-D-1-thiogalactopyranoside (IPTG, at a concentration of 1mM) when the 
culture medium had an optical density of 0.6, in order to coincide with the logarithmic 
phase of bacterial growth. The cells were then incubated with shaking at either 370C 
for 3 hours, or 160C for 24 hours; the latter protocol was found to yield higher levels 
of stable protein. 
The cell cultures were centrifuged at 10,000 x g for 15 minutes, and bacterial 
pellets were suspended in dilution buffer (20mM Tris pH 7.9, 100mM NaCl, 10% 
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glycerol, 0.2mM EDTA and 0.1% Triton X-100, supplemented with Complete Mini, 
EDTA-free Protease Inhibitor (Roche)). GST-tagged proteins were solubilised by 
sonication using a Branson Digital Sonifier at 20% amplitude for 2 separate 
sonications of one minute each. GST proteins were then recovered from the 
supernatant following centrifugation at 10,000 x g at 40C for 30 minutes. Relative 
quantification of GST fusion proteins was determined by Coomassie staining of 
resolved polyacrylamide gels. 
2.7.2 Pulldown assay 
In vitro transcription and translation of 250ng of plasmid DNA (using the 
corresponding PCDNA expression vector) was achieved by incubation with 1µl of 35S 
Methionine (1000 Ci/mmol at 10mCi/ml) and TNT T7 Quick Master Mix (Promega) 
for one hour at 300C. 
35S -labelled proteins were incubated with purified GST proteins in dilution 
buffer (20mM Tris pH 7.9, 100mM NaCl, 10% glycerol, 0.2mM EDTA and 0.1% 
Triton X-100) with rotation overnight at 40C. The solution was then added to 
glutathione-coated paramagnetic beads (Piercenet, 50µl per assay) for one hour at 40C. 
The beads were washed five times with dilution buffer, and complexes were eluted by 
boiling in 1x NuPAGE SDS Sample Buffer (Invitrogen) for 3 minutes at 1000C. 
Eluted materials were resolved by polyacrylamide gel electrophoresis, and 1% of the 
original 35S-labelled protein solution was run as an ‘input’ comparison. The gel was 
dried and exposed to x-ray film (GE Healthcare) to detect radioactive signal. 
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2.8 Retroviral infection of B3 cells 
HEK 293T cells were co-transfected with pMIG retroviral vectors (containing 
the relevant cDNA) and pCL-Eco retrovirus packaging vector, as described above 
(Section 2.3). The 293T medium was replaced after 24 hours, and viral supernatant 
was collected at both 48 and 72 hour time-points after transfection.  
Virus was added to B3 cells in the presence of HEPES (10mM) and Polybrene 
(4µg/ml). Infections were performed in a volume of 4ml per well in 6 well plates, at a 
cell density of 1 x 106 cells/ml. The virus/ cell mix was centrifuged at 700 x g for 60 
minutes (‘spinfection’), after which the viral supernatant was replaced by standard B3 
cell culture medium. Infection efficiency was determined by flow cytometric analysis 
of green fluorescent protein (GFP) expression 48 hours after infection. 
As retroviral plasmids differed in infection efficiency, the relative volumes of 
viral supernatant that were used for infections were determined by titration 
experiments. Relative infection efficiency was quantified using the following formula: 
Infective units = (% GFP positive cells * starting number of cells)/ volume of viral 
supernatant. Equal amounts of infective units were used in co-infections, and the 
corresponding volume was used for retroviral infection with each plasmid alone. 
 
2.9 Cell cycle analysis (Propidium Iodide Staining) 
Analysis of the cell cycle profile of retrovirally infected B3 cells was 
performed 48 hours after infection. Approximately 106 cells were washed once in PBS 
supplemented with 2% FCS (volume/ volume). The cells were fixed by incubation in 
cold 70% ethanol (volume/ volume) for 10 minutes on ice. After two washes in PBS/ 
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2% FCS, the fixed cells were resuspended in PBS supplemented with propidium 
iodide (50µg/ml), NP40 (0.05%) and RNase (Roche, 180µg/ml). Flow cytometric 
analysis was carried out after 30 minutes of incubation.   
 
2.10 Analysis of cellular proliferation (BrdU incorporation) 
The rates of proliferation of retrovirally infected B3 cells were assessed by 
measurement of incorporation of bromodeoxyuridine (BrdU) 48 hours after infection. 
BrdU (10µM) was added directly to a culture of 106 cells. After one hour’s incubation 
(at 370C and 5% CO2), the cells were washed twice in PBS with 1% BSA then fixed 
by incubation with 70% ethanol on ice for 30 minutes. Cellular DNA was denatured to 
single-stranded molecules by addition of 2M HCl with 0.5% Triton X-100. The 
solution was centrifuged at 500 x g for 10 minutes and the pellet was resuspended in 
0.1M Na2B4O7 (pH 8.5), in order to neutralise the acid. Following further 
centrifugation (500 x g for 10 minutes), the resultant cell pellet was resuspended in 
PBS with 0.5% Tween and 1% BSA. Flow cytometric analysis of BrdU incorporation 
was performed following incubation with a FITC-conjugated anti-BrdU antibody for 
30 minutes at room temperature.  
 
2.11 Quantitative PCR (QPCR) 
RNA was extracted from B3 cells 48 hours after retroviral infection using the 
Qiagen RNeasy mini kit, according to the manufacturer’s protocol. The Mouse Cell 
Cycle RT2 ProfilerTM PCR array was performed according to the manufacturer’s (SA 
Biosciences) instructions. All other QPCR assays were carried out following reverse 
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transcription of 1µg of RNA to cDNA using Superscript II Reverse Transcriptase 
(Invitrogen), in a final volume of 20µl.  
QPCR reactions were performed on the DNA Engine Opticon 2 (MJ Research) 
using the SYBR Green JumpStart Taq ReadyMix (Sigma-Aldrich). Reactions were 
carried out in a final volume of 25 µl per well of a 96 well plate. 1 µl of the cDNA 
reaction was added per well, in the presence of final concentrations of 400µM for each 
primer. For chromatin immunoprecipitation experiments (Section 2.11), reactions 
were performed in duplicate. For quantification of Gpr132 expression, reactions were 
performed in triplicate. In addition, a ‘no reverse transcriptase’ (no-RT) control was 
run during each Gpr132 quantification assay, in order to ensure that any detected PCR 
amplification was not caused by contamination with genomic DNA.  
The following thermal cycles were used in all QPCR experiments: 10 minutes 
at 950C, followed by 40 cycles of 15 seconds at 950C, 15 seconds at 600C and 15 
seconds at 720C. For each experiment, the threshold was set to cross a point at which 
PCR amplification was linear. 
Gpr132 expression was assessed by PCR amplification with two different 
primer sets, which gave concordant results in separate experiments. The primer 
sequences are shown in Table 2.1. Relative expression was calculated by the change-
in-threshold (−∆∆CT) method (Pfaffl, 2001), following normalisation to a 
housekeeping gene (CASC3) control. Results were analysed using Student’s paired t-
test in order to determine the statistical significance of any observed differences in 
expression between samples. 
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Table 2.1 Primer Sequences used in Gpr132 QPCR assays. 
Name Sequence 
Gpr132 Primer Set A Forward GCTACATGGCCGTGGTCTAT 
Gpr132 Primer Set A Reverse GGTGAAACGCAGGTAGTGGT 
Gpr132 Primer Set B Forward CGTCACCATCTTCCTGGTCT 
Gpr132 Primer Set B Reverse ACGTAGATGATGGGGTCAGC 
CASC3 Forward AGCTAACGATGCTGCTGATTC 
CASC3 Reverse TCCAAGTGCTTAGGGCCTTTT 
 
2.12 Chromatin immunoprecipitation (ChIP) 
2.12.1 Chromatin Isolation 
Chromatin was isolated from B3 cells 48 hours after retroviral infection. 
Approximately 107 cells were fixed and cross-linked with formaldehyde (1%) at 370C 
for 10 minutes. The cross-linking reaction was terminated by addition of glycine 
(0.125M) and incubation at room temperature for 10 minutes, after which the cells 
were washed three times in PBS at 40C (at 700 x g for 5 minutes each time). 
Cells were resuspended in a swelling buffer (25mM HEPES pH 7.9, 1.5mM 
MgCl2, 10mM KCl and 0.1% NP40 supplemented with Complete Mini Protease 
Inhibitor (Roche)). This solution was kept on ice for 10 minutes in order to lyse the 
cells, and was then homogenised using a Dounce homogeniser (50 strokes) and 
subjected to centrifugation (3000 x g at 40C for 8 minutes). The resultant nuclear 
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pellet was resuspended in sonication buffer (50mM HEPES, 140mM NaCl, 1mM 
EDTA, 1% Triton X-100, 0.1% sodium deoxycholate and 0.1% sodium 
dodecylsulphate supplemented with Complete Mini Protease Inhibitor (Roche)) and 
sonicated at high intensity using a Bioruptur sonicator (Diagenode) for 30 minutes in 
total (5 seconds on/ 5 seconds off). 
The sizes of the chromatin fragments were verified by agarose gel 
electrophoresis and if satisfactory (a range of 500-1000 base pairs), the chromatin was 
recovered from the supernatant following centrifugation (10,000 x g at 40C for 10 
minutes). The chromatin concentration was determined following alkaline lysis (1:10 
dilution in 0.1M NaOH) using a spectrophotometer, by measurement of absorbance at 
260 nm. Chromatin samples were diluted to equal concentrations and aliquots of 
equivalent amount were snap frozen in liquid nitrogen and stored at -800C until 
required.  
2.12.2 Immunoprecipitation 
5µg of anti-FLAG M2 antibody (Sigma-Aldrich) was coupled to 40 µl Protein 
G Dynabeads (Sigma-Aldrich) for two hours at 40C. Following removal of unbound 
antibody, 100µg of chromatin was added to the beads and incubated overnight at 40C 
with rotation. 
The beads were washed four times at 40C in the following sequence: once with 
sonication buffer; once with wash buffer ‘A’ (50mM HEPES, 500mM NaCl, 1mM 
EDTA, 1% Triton X-100, 0.1% sodium deoxycholate and 0.1% sodium 
dodecylsulphate); once with wash buffer ‘B’ (20mM Tris pH 8.0, 1mM EDTA, 
250mM LiCl, 0.5% NP40, 0.5% sodium deoxycholate); and finally with Tris-EDTA 
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(TE, pH 8.0). The beads were resuspended in fresh TE (pH 8.0) and transferred to a 
new Eppendorf tube, in order avoid subsequent detection of material that bound non-
specifically to the walls of the original tube. 
Following removal of TE, the beads were suspended in an elution buffer 
(50mM Tris pH 8.0, 50mM NaCl, 1mM EDTA, 1% sodium dodecylsulphate 
supplemented with DNase-free RNase at 20µg/ml) and incubated overnight at 680C, 
in order to reverse the cross-linking of the chromatin. In addition, non-IP’d chromatin 
equivalent to 10% of the original IP (which would subsequently be used an ‘input’ 
comparison for QPCR amplification) was reverse cross-linked simultaneously.  
Recovered chromatin was treated with Proteinase K (200 µg/ml) for two hours, after 
which DNA was purified using a PCR purification kit (Qiagen). The concentration of 
the recovered DNA was calculated using PicoGreen reagent (Invitrogen). 
2.12.3 QPCR 
The QPCR procedure is described in Section 2.11. Each amplification was 
performed on equivalent volumes of recovered DNA, and a 10% ‘input’ comparison 
that facilitated relative quantification of the observed IP. The sequences of the primers 
that were used to amplify Gpr132 Regions A and B, and ‘background’ regions 1 and 2 
(discussed in Section 6.1) are listed in Table 2.2. 
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Table 2.2 Primers used in QPCR analysis of ChIP experiments.  
 
Name Sequence 
Gpr132 Region A; Primer Set 1, Forward CGCAAAATCAGCATGAAGAA 
Gpr132 Region A; Primer Set 1, Reverse TGGGGCTCTGAAATATTGGT 
Gpr132 Region A; Primer Set 2, Forward TACAGACAACCAGGCACCAG 
Gpr132 Region A; Primer Set 2, Reverse TCATGCTGATTTTGCGTTTC 
Gpr132 Region B; Primer Set 1, Forward GAGGGCTGCTCAGGATGAT 
Gpr132 Region B; Primer Set 1, Reverse AGTGGTGGGTACCAGCAGTG 
Gpr132 Region B; Primer Set 2, Forward CTCACCCAACCCCTAACAGA 
Gpr132 Region B; Primer Set 2, Reverse CACGAACAGCTGCTTTCAGA 
Background Region 1, Forward CAGAGGACAGCTAGGCAGAGA 
Background Region 1, Reverse GAGCAGACTCATTAGGGCAAA 
Background Region 2, Forward TGATGACAGATCAAGCCAGGT 
Background Region 2, Reverse TTGTAACATGGGGTCGTG 
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Chapter 3 
Characterisation of a physical interaction 
between Ikaros and Foxp1 
Interplay between transcription factors is known to be important for the 
regulation of gene expression during B-lymphopoiesis (Busslinger, 2004). As Ikaros 
and Foxp1 are expressed contemporaneously through several stages of B cell 
differentiation, this raised the possibility that these proteins might interact 
functionally. If this is the case, disruption of such an interaction (for example, as a 
consequence of the acquired genetic changes to Ikaros that are typically observed in 
Ph+ B-ALL) could result in changes to B-cell transcriptional programmes. 
The above considerations suggested the possibility of a physical association 
between the two proteins. Prior to my commencing this project, this hypothesis was 
initially tested in pre-B-cells, as expression of each factor is relatively high at this 
stage of differentiation. Co-immunoprecipitation (co-IP) experiments were performed 
on protein lysates obtained from wild-type (WT) murine fetal liver pre-B-cells by Dr. 
Renae Domaschenz. Lysates were subjected to IP with anti-Ikaros and anti-Foxp1 
antibodies, and immunoblots were performed using the eluates. Figure 3.1 shows an 
anti-Foxp1 immunoblot (generated by Dr. Domaschenz) that demonstrated the 
presence of endogeneous Foxp1 and successful IP of Foxp1 using an anti-Foxp1 
antibody. Critically, there was also significant pulldown of Foxp1 following IP with 
the anti-Ikaros antibody, demonstrating co-IP of the proteins in these cells. The results 
of this co-IP, together with results from repeat confirmatory experiments formed the 
basis for the work described in this thesis. 
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Figure 3.1 Ikaros and Foxp1 interact in murine fetal liver pre-B-cells. Protein 
extracts from murine fetal liver pre-B-cells were subjected to IP with anti-Foxp1 and 
anti-Ikaros antibodies. An anti-Foxp1 immunoblot is shown. An arrow indicates the 
presence of full-length Foxp1 (Foxp1A) in the input lane. Foxp1A and some shorter 
splice isoforms were precipitated by both anti-Ikaros and anti-Foxp1 antibodies, but 
not by normal IgG control antibody. IgH indicates the presence of immunoglobulin 
heavy chain from the IP antibody. 
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Input Foxp1Ikaros IgG
IP Antibody
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3.1 Murine Ikaros and Foxp1 interact in vivo 
The physical interaction between Ikaros and Foxp1 was investigated using an 
expression system based on Human Embryonic Kidney (HEK) 293T cells (henceforth 
referred to as ‘293T cells’). 293T cells were transfected with expression vectors that 
encode murine Ikaros and Foxp1 proteins, containing an N-terminal epitope tag (HA-
Ikaros and FLAG-Foxp1). The addition of an epitope tag to the construct facilitated 
subsequent IP, using anti-HA or anti-FLAG antibodies.  
Cells were co-transfected with expression vectors that encode HA-Ikaros and 
FLAG-Foxp1, and IP was performed on protein lysates that were extracted 48 hours 
after transfection. Figure 3.2 shows the results of an IP carried out with an anti-FLAG 
antibody, which recognises the FLAG-tagged Foxp1. Probing of the blot with anti-HA 
showed a significant pulldown of HA-Ikaros, demonstrating the in vivo interaction 
between the two proteins in this system (Figure 3.2, left panel). The reciprocal 
experiment was carried out using IP with a polyclonal anti-Ikaros antibody, which I 
found to be more efficient in IP than the anti-HA antibody. Detection of Foxp1 by 
Western blotting of the precipitated proteins with anti-FLAG antibody provided 
further confirmation of the association between the two proteins (Figure 3.2, right 
panel). 
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Figure 3.2 Murine Ikaros and Foxp1 interact in vivo, when ectopically expressed 
in 293T cells. Protein extracts from 293T cells that were co-transfected with HA-
tagged Ikaros and FLAG-tagged Foxp1 were subjected to IP and analysed by Western 
blotting with anti-HA antibody (right panel) and anti-FLAG antibody (left panel). The 
antibody used for the IP is indicated above each blot. 
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3.2 Murine Ikaros and Foxp1 proteins interact in vitro 
Reciprocal IP of Ikaros and Foxp1 provides strong evidence of an interaction 
between these proteins in vivo. However, this approach does not differentiate between 
a direct protein-protein interaction and an indirect association as part of a larger 
multiprotein complex. As transcription factor activity entails physical contact with a 
wide range of partner proteins, IP in vivo could result in pulldown of associated 
complexes. Although a finding that the association is indirect would not necessarily 
preclude the possibility of a functionally significant interaction, the confirmation of a 
direct physical association would increase the likelihood that Ikaros and Foxp1 
proteins act together in the regulation of gene expression in B-cells.    
Evidence of direct interaction can be obtained by co-precipitation of purified 
proteins in vitro in a cell-free system. These systems typically involve the addition of 
high-affinity protein tags to the molecules of interest, in order to facilitate subsequent 
purification. An example of this system entails the fusion of a protein of interest to a 
high-affinity Glutathione-S-Transferase (GST) tag and expression in bacteria under 
the control of an Isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible promoter. 
The protein can then be isolated and precipitated by addition to paramagnetic beads 
that are coated with Glutathione (GSH), the substrate for GST (see Methods Section 
2.7). Competent bacteria were transformed with expression vectors that encode GST 
fusion proteins of either murine Ikaros or Foxp1. Bacteria were also transformed with 
an ‘empty’ vector that encodes GST only. The latter control is necessary, as inclusion 
of a GST protein in the subsequent experiments ensures that any detected precipitation 
does not simply reflect non-specific association with the GST molecule.  
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Following optimisation of the purification procedure, the quality of each fusion 
protein preparation was assessed by precipitation using GSH-coated paramagnetic 
beads and analysis by SDS-polyacrylamide gel electrophoresis followed by 
Coomassie staining. Precipitation of the bacterially expressed GST-Ikaros fusion 
protein consistently gave a pulldown that was mainly composed of smaller products, 
reflecting either protein instability or premature termination of transcription or 
translation. Attempts at performing pulldowns using this preparation (including 
attempted precipitation of Ikaros protein as a positive control) were unsuccessful, 
indicating that the purified GST-Ikaros protein was not suitable for use in these 
experiments. For this reason, we focused our efforts on assessment of whether there is 
a direct interaction between GST-Foxp1 and an Ikaros protein which was radio-
labelled by coupled in vitro transcription/ translation in the presence of 35S-methionine 
(see Methods Section 2.7). 
The 35S-labelled Ikaros was incubated with either purified GST or GST-Foxp1 
fusion protein and was then added to GSH-coated paramagnetic beads. Complexes 
were eluted and resolved by SDS-polyacrylamide gel electrophoresis. The results 
showed a clear band for the 35S-Ikaros in the GST-Foxp1 pulldown, which is not 
present in the GST lane (Figure 3.4). A Coomassie stain of a mock pulldown 
performed at the same time showed equivalent elution of GST and GST-Foxp1, 
indicating that similar amounts of protein were bound to the GSH-coated 
paramagnetic beads (Figure 3.3, below). These in vitro data confirm the existence of a 
direct interaction between murine Ikaros and Foxp1 proteins, without the requirement 
for formation of larger multiprotein complexes that contain both proteins. 
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Figure 3.3 Coomassie stain of a mock GST pulldown. A mock pulldown was 
performed at the same time as the GST pulldown depicted in Figure 3.4 (overleaf) and 
resolved by polyacrylamide gel electrophoresis. Coomassie staining of the gel showed 
that similar amounts of GST and GST-Foxp1 were bound to the GSH-coated beads.  
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Figure 3.4 Murine Ikaros and Foxp1 interact in vitro. 35S-labelled Ikaros was 
transcribed and translated in vitro, incubated with either purified GST or GST-Foxp1 
fusion protein and then added to GSH-coated paramagnetic beads. Immunocomplexes 
were eluted and resolved by polyacrylamide gel electrophoresis and the presence of 
35S-labelled protein was detected by autoradiography.  
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Ikaros
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3.3 Ikaros and Foxp1 interaction is mediated by the DNA-binding 
domains of both proteins 
In order to discover which regions of each factor are necessary for protein-
protein interaction, we generated deletion constructs, which lacked specific domains 
of the protein that have been previously described to have functional significance 
(Cobb et al., 2000; Molnar and Georgopoulos, 1994; Wang et al., 2003). Schematic 
representations of the structure of each protein and of the deletion mutants are shown 
in Figures 3.5 (Ikaros) and 3.7 (Foxp1). 
As discussed in the previous section, the association between GST-Foxp1 and 
radio-labelled Ikaros was readily demonstrable in vitro. This method detects direct 
interaction of the proteins, without the requirement for participation in multiprotein 
complexes that may be formed in vivo. Therefore this system was used to test the 
binding of deletion mutants of Ikaros to WT Foxp1. Mutants were transcribed and 
translated in vitro and incubated with both GST and GST-Foxp1. Most deletion 
mutants interacted with GST-Foxp1 to a similar extent to that of the WT protein 
(Figure 3.6). However, deletion of exons 3-6 (which encompasses the coding region 
for the central zinc finger domain and therefore corresponds to the non-DNA-binding 
IK6 isoform) abrogated the interaction with Foxp1 almost completely (Figure 3.6). 
This indicates that a significant part of the interaction is mediated by this region of the 
Ikaros protein.  
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Figure 3.5 Schematic representation of Ikaros protein and deletion mutants. Zinc 
fingers are represented by filled boxes. Lines indicate the deletions that were tested in 
in vitro interaction experiments (Figure 3.6). The numbering indicates the amino acid 
position of each deletion, e.g. 54C encompasses the first 54 amino acids. The IK6 
deletion extends from residues 50 to 233. The N458 deletion comprises the final 62 
amino acids of the protein. 
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Figure 3.6 Mapping of the interaction domain of Ikaros. WT Ikaros and deletion 
mutants (depicted schematically along with molecular weights) were transcribed and 
translated in vitro and pulldown was performed with either GST or GST-Foxp1. 
Pulldown with GST alone is associated with non-specific precipitation of shorter 
translated proteins in most experiments. These shorter products are not seen following 
in vitro translation of the smaller IK6 protein. All experiments were performed at least 
twice. 
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 Due to the difficulties that were encountered when purifying intact GST-Ikaros 
(see Section 3.2), the 293T cell system was used to IP FLAG-tagged Foxp1 deletion 
mutants, using an anti-Ikaros antibody. Interaction of most deletion mutants of Foxp1 
was similar to that of the WT protein, however deletion of 543 base pairs that encode 
the forkhead region resulted in an abolition of the association (Figure 3.8). Similar to 
the interaction region of Ikaros, this part of Foxp1 has been shown to mediate DNA-
binding (Wang et al., 2003). 
 
 
 
 
Figure 3.7 Schematic representation of Foxp1 protein and deletion mutants. 
Patterned boxes indicate the labelled structural domains. Deletion mutants lacking 
specific functional regions were tested in interaction assays shown in Figure 3.8. 
Foxp1C is an isoform that lacks the polyglutamine and glutamine-rich regions (Amino 
acids 1-261). All other deletion mutants lack the amino acids that code for the relevant 
functional region, as shown. 
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Figure 3.8 Mapping of Foxp1 interaction domain. 293T cells were co-transfected 
with WT Ikaros and either WT Foxp1 or Foxp1 deletion mutants that lack specific 
structural domains (depicted schematically). IP using an anti-Ikaros antibody resulted 
in pulldown of Foxp1 and most deletion mutants (indicated by block arrows next to 
the input lane). A Foxp1 mutant which lacks the forkhead region (which mediates 
DNA-binding) was not precipitated. All experiments were performed at least twice. 
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As each of the regions that were found to mediate protein-protein association 
has also been shown to be necessary for binding to DNA, we considered the 
possibility that demonstration of the association was dependent on the presence of 
DNA in the IP reaction (and therefore, isoforms that do not bind DNA would not be 
precipitated). In order to ensure that the preceding results did not simply reflect the 
isolation of DNA-bound complexes, IP was also performed in the presence of either 
ethidium bromide (which disrupts DNA-protein interactions (Lai and Herr, 1992)) or 
DNase I. Representative results of this analysis are shown in Figure 3.9 and show that 
the IP was unaffected by ethidium bromide or DNase I. 
 
 
Figure 3.9 Co-IP of murine Ikaros and Foxp1 proteins is not DNA-dependent. 
Protein lysates were treated with either ethidium bromide or DNaseI, in order to 
disrupt DNA-protein interactions. At least two experiments were performed using 
either condition. IP was performed in the manner previously described. A 
representative IP experiment following DNase treatment of protein lysates is shown.  
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3.4 The human IK6 deletion abolishes interaction with human 
FOXP1 
The DNA sequences of both Ikaros and Foxp1 are highly conserved between 
mice and humans (Brown et al., 2008; Cortes et al., 1999), which raised the strong 
possibility of an equivalent interaction between the human forms of the proteins. In 
order to test whether the human proteins interact, IP was performed on protein extracts 
from 293T cells that had been transfected with FLAG-tagged human FOXP1 and 
either WT human Ikaros, or human Ikaros isoform IK6. The results of this IP are 
shown in Figure 3.10. WT Ikaros was precipitated by an anti-FLAG antibody, but the 
same antibody did not pull down IK6. The reciprocal anti-Ikaros IP showed 
corresponding results (i.e. lack of pulldown of FLAG-Foxp1 by IK6), indicating that 
the central zinc finger domain of human Ikaros is required for interaction with human 
FOXP1. This pattern of association was also observed in an in vitro pulldown assay. 
WT Ikaros was pulled down efficiently by GST-FOXP1, whereas IK6 gave almost no 
detectable pulldown (Figure 3.11). 
These findings were further confirmed by performing anti-FOXP1 IP on 
protein extracts from human B-ALL cell lines that exhibit differing patterns of Ikaros 
isoform expression. The predominant isoform that is expressed in the REH ALL line 
is WT Ikaros. IP of protein extracts from this cell line showed precipitation of WT 
Ikaros by an anti-FOXP1 antibody (Figure 3.12 (left panel). The SUP-B15 cell line 
expresses the IK6 isoform, and a reduced amount of WT protein. IP with the anti-
FOXP1 antibody failed to pull down the IK6 isoform in this case (Figure 3.12). In 
addition, several experimental replicates in this line showed that anti-FOXP1 IP of 
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WT Ikaros was either reduced or absent. This may reflect the reduced levels of WT 
protein in the SUP-B15 line (in comparison with REH cells), or may also be caused 
by a sequestration effect exerted by IK6 on WT Ikaros (Molnar et al., 1996). Overall, 
these results provide further confirmation that the DNA-binding domain of Ikaros is 
required for interaction with FOXP1 in vivo and in vitro. 
 
 
 
 
 
 
Figure 3.10 Human IK6 does not interact with human FOXP1 in a 293T cell 
expression system. 293T cells were co-transfected with FLAG-tagged human 
FOXP1, and either WT human Ikaros, or human IK6. Whole cell extracts were IP’d 
with anti-Ikaros or anti-FLAG and probed with anti-Ikaros (left-hand panel) or anti-
FOXP1 (right-hand panel). Confirmation of the result was seen in a further repeat 
experiment. 
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The corollary of the observation that the DNA-binding domains of each protein are 
required for the interaction is that these regions should be sufficient in themselves for 
association of the factors to occur. We attempted to assess this by using a construct 
that contains the cDNA which codes for the four DNA-binding zinc fingers of the 
Ikaros protein. This was transcribed and translated in vitro, and pulldown with GST-
Foxp1 was assessed. Unfortunately, this truncated protein was not expressed to any 
great extent using this system and it was therefore not possible to assess its binding. 
We therefore cannot formally rule out the possibility that abnormal folding of either or 
both deletion mutant may have caused false negative results in the interaction assays.  
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Figure 3.11 Human IK6 does not interact with human FOXP1 in vitro. WT Ikaros 
and IK6 were transcribed and translated in vitro in the presence of 35S-methionine and 
analysed for interaction with GST or GST-FOXP1 as previously described (Figure 
3.3). Confirmation of the result was obtained in a further repeat experiment. 
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Figure 3.12 Anti-FOXP1 IP of Ikaros isoforms in human leukaemia cell lines. 
WT Ikaros was precipitated by an anti-FOXP1 IP of protein extracts from the REH 
cell line. The same antibody failed to IP the IK6 isoform in lysates obtained from the 
SUP-B15 cell line. In addition, no IP of WT Ikaros was seen in the SUP-B15 line. IgG 
IP controls are negative in all cases. Two further repeat experiments showed very 
weak interaction of WT Ikaros with FOXP1. 
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3.5 Summary 
 The hypothesis that Ikaros and Foxp1 might interact during B-cell development 
arose from established concepts of transcription factor interplay during 
haematopoiesis, and the observation that the two factors are expressed at similar 
stages of differentiation. Co-IP of the proteins in murine fetal liver pre-B-cells 
provided the first evidence of a physical association that might involve a functional 
interaction between the two proteins. 
In order to investigate this possibility further, the reproducibility of the 
interaction was confirmed in several different systems. Ikaros and Foxp1 were shown 
to associate in vivo in a DNA-independent manner when ectopically expressed in 
293T cells. The finding that interaction between the purified proteins could also be 
detected in vitro reinforces this DNA-independence, and suggests that the physical 
association is a direct one. Experimental assessment of human proteins using the same 
systems yielded identical results, suggesting that the interaction is evolutionarily 
conserved. 
 Elucidation of the interaction region of the relevant proteins showed that 
contact was mediated through the respective DNA-binding domains. This finding 
raises important questions about the potential downstream effects of alterations in the 
relevant amounts of each protein (or their isoforms) on developmentally-regulated 
gene transcription. In the following chapters, I will discuss how the functional 
significance of Ikaros-Foxp1 interplay was investigated. 
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Chapter 4 
Role of the Ikaros/Foxp1 interaction in 
regulating the pre-B cell cycle 
We considered that the demonstrated physical interaction between Ikaros and 
Foxp1 could affect transcription factor activity by several diverse mechanisms. In one 
scenario, Ikaros/ Foxp1 association might increase the affinity of one or both factors 
for target gene sequences (for example through induction of protein conformational 
changes), thereby stimulating transcription. The converse hypothesis would predict 
that association of the proteins negatively regulates target gene expression through 
inhibition of DNA binding. It could also be possible that the consequences of Ikaros/ 
Foxp1 contact might depend on the presence or absence of additional associated 
factors, so that the effects of the interaction may vary according to gene locus and/ or 
cell type.  
The fact that contact between Ikaros and Foxp1 is mediated by known DNA-
binding regions led us to speculate that one likely outcome of protein-protein 
interaction would be abrogation of DNA binding of one or both factors. This 
hypothesis predicts that the amount of each factor that is available for gene regulation 
is affected by the relative quantity of the interacting molecule, which would otherwise 
occupy the DNA-binding domain. In this scenario (depicted in Figure 4.1, and which 
is simplified by assuming mutually exclusive binding of each factor), a reduction in 
the quantity of one protein would ‘liberate’ the other partner to bind gene regulatory 
elements and alter transcription. 
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Figure 4.1 Model of the hypothetical effects of changes in the amounts of Ikaros 
and/or Foxp1 on expression of target genes. A simplified model (predicated on the 
hypothesis that protein-protein interaction inhibits DNA binding, and that DNA 
binding of each factor is mutually exclusive) of the effects of changes in relative 
protein levels is shown. Interacting factors are depicted as coloured pies, and DNA as 
a spiral. The left side of the figure shows ‘baseline’ levels of yellow proteins, which 
occupy the DNA-binding domains of the blue proteins; the non-bound fraction is free 
to bind DNA and alter gene expression. On the right side of the figure, reduced levels 
of the yellow protein (‘imbalance’) result in increased availability of non-bound blue 
proteins, which can bind DNA and alter expression of gene targets.  
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Fluctuations in the levels of either factor (during normal development, or as a 
consequence of pathological derangement) could therefore cause changes in cellular 
gene expression and phenotype. This would have particular relevance for cases of B-
ALL that have genomic deletions of the IKZF1 gene and expression of the non-
FOXP1-interacting IK6 isoform (Section 1.6). If the model shown in Figure 4.1 is 
correct, this would be expected to increase the availability of FOXP1 for binding to 
DNA, thereby altering expression of FOXP1 gene targets. 
In order to examine the effects of altered balance between Ikaros and Foxp1, 
the relative level of each protein was manipulated by retroviral infection in a pre-B-
cell experimental model. The B3 cell line (Fisher et al., 1995) was used, as these cells 
are highly amenable to retroviral infection, and correspond phenotypically to the large 
pre-B-cell stage of differentiation. 
B3 cells were infected with retroviruses that encode either Ikaros or Foxp1, or 
with both constructs in a ‘co-infection’. A bicistronic retroviral vector was used, in 
which the same gene promoter controls expression of both of the gene of interest 
(Ikaros or Foxp1) and an internal ribosome entry site (IRES)-green fluorescent protein 
(GFP) sequence. This system enables infected cells to be readily detected by 
measurement of GFP expression. Infection rates were consistently greater than 95% 
(Figure 4.2), obviating the need for cell sorting and further manipulation which might 
otherwise affect experimental results. Assessment of the resultant cellular phenotype 
was performed 48 hours after infection, and these results are detailed in the following 
sections.
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Figure 4.2 Rates of retroviral infection of B3 cells. Infection rates were determined 
by green fluorescent protein (GFP) expression (measured on the x axis) 48 hours after 
infection. The percentages of GFP-expression (indicating infected cells) are shown in 
this representative experiment. The experiments described in this chapter were 
performed four times in total. 
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4.1 Overexpression of Foxp1 is associated with G2 cell cycle arrest 
As both Ikaros and Foxp1 have been described to affect the progression of the 
cell cycle in haematopoietic cells (Feng et al., 2009; Ma et al., 2010), we considered 
the possibility that interaction between the proteins influences the regulation of this 
process in lymphocytes. This led us to hypothesise that alterations in the relative 
amounts of either factor would perturb lymphoid cell cycle homeostasis. 
In order to test this hypothesis, the cell cycle profiles of retrovirally-infected 
cells were determined by staining of DNA with propidium iodide (PI). This analysis 
relies on the fact that cells in G2/M contain twice as much DNA as cells in G1. Flow 
cytometric assessment therefore shows two peaks of cellular DNA content 
corresponding to these phases, while all cells that have intermediate amounts are 
considered to be in S phase. PI staining of retrovirally transduced cells revealed that 
Foxp1 infection resulted in a large increase (at least two-fold) in the proportion of 
cells in the G2 phase of the cycle, compared with an empty vector control (Figure 
4.3). Co-infection of Ikaros with Foxp1 consistently and completely abrogated this 
phenotype with the co-infected cells showing cell cycle profiles that were very similar 
to the empty vector control. As expected, infection with Ikaros alone resulted in an 
increased proportion of cells in the G1 phase of the cycle, due to its inhibitory effect 
on G1/S transition (Ma et al., 2010). Each of these results was highly reproducible 
across five replicate experiments. 
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Figure 4.3 Cell Cycle Profile of infected B3 cells. Cell cycle status was assessed by 
propidium iodide (PI) staining 48 hours after retroviral infection. The flow cytometric 
pattern of a representative experiment is shown in the upper part of the figure. A 
substantial increase in the proportion of cells in the G2 phase of the cycle is observed 
following infection with Foxp1. A graphical representation of results averaged across 
four separate experiments is shown in the bottom panel. 
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In order to confirm that levels of ectopically expressed Foxp1 were similar in 
single infections and co-infections, immunoblotting of protein extracts from infected 
pre-B-cells was performed. The levels of FLAG-Foxp1 following co-infection with 
Ikaros were equivalent to those seen following Foxp1 infection alone. This indicates 
that the observed abrogation of cell cycle phenotype does not simply reflect a 
reduction in FLAG-Foxp1 expression due to co-infection with another retrovirus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Expression of FLAG-Foxp1 and HA-tagged Ikaros in retrovirally 
infected B3 cells.  The levels of ectopic protein expression were determined by 
immunoblotting of protein extracts from infected pre-B-cells. The levels of FLAG-
Foxp1 are similar in cells infected with Foxp1 alone, and cells co-infected with Ikaros 
and Foxp1. 
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4.1.1 Overexpression of Foxp1 is associated with reduced cellular 
proliferation 
There are two alternative explanations for the observation that increased Foxp1 
expression resulted in an increased proportion of cells in the G2 phase of the cell 
cycle. The first possibility is that higher levels of Foxp1 caused a delay or arrest of 
cells in G2. Alternatively, overexpression of Foxp1 might have stimulated higher rates 
of cycling, thereby generating a larger G2 fraction. In order to discriminate between 
these two possibilities, cellular proliferation was assessed by measurement of 
bromodeoxyuridine (BrdU) incorporation. This measure quantifies the amount of 
BrdU that has been incorporated into newly synthesised DNA during S phase, and 
thus provides a surrogate measure of cellular proliferation.    
The results of a representative experiment are shown in Figure 4.5. Foxp1 
infection was associated with a reduction in BrdU incorporation that was consistent 
with a diminished rate of proliferation relative to an empty vector control (Figure 4.5). 
This indicated that the observed cell cycle changes were not due to increased rates of 
cycling, but occurred because of G2 arrest. As expected from previously published 
data (Ma et al., 2010), infection with Ikaros also caused a reduction in cellular 
proliferation. Co-infection of Ikaros with Foxp1 was associated with similar 
reductions in proliferation to those seen following infection with either factor alone.  
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Figure 4.5 Measurement of proliferation of retrovirally infected B3 cells. Cellular 
proliferation was assessed by measurement of bromodeoxyuridine (BrdU) 
incorporation. The percentages of cells that have incorporated BrdU (and are therefore 
proliferating) are indicated.  
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4.2 Foxp1-mediated G2 cell cycle arrest is associated with increased 
expression of Gpr132 
We reasoned that the mechanistic basis of the observed G2 arrest in Foxp1 
overexpressing cells could be transcriptional activation (or repression) of a specific 
gene (or genes) by Foxp1. Co-infection with Ikaros would abrogate these effects by 
occupation of the Foxp1 forkhead domain, thereby reducing Foxp1 DNA-binding 
activity to baseline levels. In order to measure the transcriptional changes that 
followed Foxp1 overexpression, RNA was extracted from retrovirally infected B3 
cells and quantitative PCR (QPCR) analysis was performed. A commercially available 
QPCR-based array (Qiagen) was initially used to determine the expression of a range 
of cell cycle-associated genes (84 in total), with the aim of identifying candidate genes 
for further analysis. The gene that showed the greatest increase in expression 
following Foxp1 infection was Gpr132 (2.8-fold, data not shown). This gene encodes 
the G2A protein, a stress-inducible G protein-coupled receptor which has been 
described to mediate a variety of effects in blood cells, including monocyte activation 
and T-cell chemotaxis (Bolick et al., 2009; Osmers et al., 2009). Notably, G2A has 
previously been described to induce G2 arrest when ectopically expressed in human 
fibroblasts (Le et al., 2002; Weng et al., 1998) and we therefore considered it to be a 
prime candidate to mediate the observed cell cycle effects. 
The results from the cell cycle array were validated by analysing Gpr132 
expression in three separate Foxp1 overexpression experiments. QPCR was carried 
out using two sets of primers for Gpr132 mRNA, and results were highly concordant 
between primer sets. Expression levels were calculated using the change-in-threshold 
(−∆∆CT) method, with normalisation to an internal housekeeping gene control 
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(CASC3). The results of the expression analysis are shown in Figure 4.6. Foxp1 
infection consistently resulted in increases of between 1.5- and 4-fold in the levels of 
Gpr132 relative to infection with an empty vector control. The mean increase in 
expression in assays of material isolated from three biological replicates was 2.33 ± 
0.6 (mean ± SEM). 
In cells that were co-infected with Ikaros and Foxp1, the ratio of Gpr132 
expression relative to empty vector was 1.08 +/- 0.29, indicating that co-infection with 
Ikaros abrogates Foxp1-mediated induction of Gpr132 transcription. The differences 
in expression that were observed following Foxp1 single infection and Ikaros/ Foxp1 
co-infection were analysed using a Student’s paired t-test, and were found to be 
statistically significant (p < 0.05). 
Infection with Ikaros alone resulted in a decreased ratio of Gpr132 relative to 
empty vector (0.77 ± 0.19), which was likely to be caused by interaction of 
ectopically-expressed Ikaros with endogeneous Foxp1. According to our model, 
enhancement of gene expression by Foxp1 would be inhibited as a consequence of 
occupancy of the DNA-binding domain of the endogeneous protein by ectopically-
expressed Ikaros, and these results provide further support for this type of model. 
Attempts were made to confirm a corresponding increase in Gpr132 at the 
protein level, but immunoblotting using a commercially available antibody was 
unsatisfactory. 
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Figure 4.6 Expression of Gpr132 in retrovirally infected B3 cells. Expression 
analysis was carried out on RNA extracted from cells 48 hours after retroviral 
infection. Mean changes in expression from assays of three biological replicates are 
shown. Levels of Gpr132 are expressed relative to levels in cells infected with the 
control empty vector. Foxp1 infection consistently resulted in increased Gpr132 
expression, while co-infection of Ikaros with Foxp1 was associated with Gpr132 
levels that were equivalent to empty vector control. The difference between these 
values was statistically significant, as shown. Ikaros infection alone resulted in 
reduced Gpr132 expression. Error bars indicate standard error of the mean (SEM).  
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4.3 Summary 
Infection of B3 cells with retroviral constructs that encode either Ikaros or 
Foxp1 provided a model for studying the potential effects of quantitative imbalances 
of either factor. The most striking phenotype was seen following infection with 
Foxp1, which consistently resulted in an approximately two-fold increase in the 
proportion of cells in the G2 phase of the cell cycle. The associated reductions in 
cellular proliferation indicated that the observed effects occurred as a result of G2 
arrest. 
Co-infection of Ikaros and Foxp1 was associated with cell cycle profiles that 
were similar to the profiles obtained with the empty vector control. Ikaros may 
therefore be considered to have ‘rescued’ the cell cycle phenotype, presumably 
through inhibition of Foxp1-mediated alterations in gene expression. Initial screening 
of a range of candidate genes using a QPCR-based array identified Gpr132 as a 
potential mediator of G2 arrest. Confirmatory analysis showed consistent Foxp1-
mediated upregulation of Gpr132 expression, which was ‘rescued’ by co-infection 
with Ikaros. 
Our mapping of the interaction domains that mediate protein-protein 
association (Chapter 3) led us to postulate that phenotypic rescue by co-infection was 
dependent on Ikaros occupancy of the Foxp1 forkhead domain, and a reduction in the 
amount of Foxp1 that is available to bind DNA. This hypothesis was examined further 
in the experiments described in the following chapters. 
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Chapter 5 
Verification of a lack of functional interaction between 
IK6 and Foxp1 in murine pre-B-cells 
The experimental results described in the preceding chapter led us to reason 
that the preservation of steady-state ratios of Ikaros and Foxp1 proteins is critical for 
maintaining cell cycle homeostasis in pre-B-cells, and that regulation of the levels of 
expression of Gpr132 is central to this requirement. Overexpression of Foxp1 (thereby 
altering cellular Ikaros/ Foxp1 ratios) led to G2 arrest, which was associated with 
increases in Gpr132 expression. Restoration of equivalent Ikaros/Foxp1 ratios (by co-
expression of similar amounts of each protein) abolished both the phenotype of G2 
arrest and induction of Gpr132 expression. We hypothesised that co-infection of an 
Ikaros isoform that does not interact with Foxp1 would fail to alter Foxp1-induced 
transcriptional changes and would not restore a steady-state cell cycle profile. 
In order to test this theory, several additional pre-B-cell retroviral infection 
experiments were performed. B3 cells were infected with either WT Ikaros, Foxp1, or 
both constructs in a co-infection. Cells were also co-infected with Foxp1 and the 
Ikaros isoform IK6, which was shown not to interact with Foxp1 either in vivo or in 
vitro (Chapter 3). If the model shown in Figure 4.1 is correct, co-infection of Foxp1 
with IK6 would be expected to have no effect on the cell cycle phenotype or on 
Gpr132 levels. 
115 
 
5.1 Co-expression of IK6 does not abrogate Foxp1-induced G2 
arrest in pre-B-cells 
Infection rates of all constructs (as determined by GFP expression) exceeded 
95%, which again obviated the necessity for cell sorting and further manipulation that 
might otherwise affect experimental results (Figure 5.1). Phenotypic assessment was 
made 48 hours after infection, as with previous experiments. Consistent with the 
results described in Chapter 4, infection with Foxp1 was associated with G2 arrest, 
and this phenotype was ‘rescued’ by co-infection with WT Ikaros. Co-infection of IK6 
with Foxp1 resulted in the same G2 arrest phenotype that was seen observed with 
Foxp1 infection alone. Infection with IK6 alone had no effect on cell cycle profiles 
(Figure 5.2 (a)). These results were reproducible in three separate experiments. 
Averages of the observed cell cycle profiles are shown in Figure 5.2 (b). 
The observation that IK6 failed to ‘rescue’ the cell cycle phenotype shows that 
the central zinc finger domain of Ikaros is required for abrogation of Foxp1-related 
cell cycle effects by WT Ikaros. The fact that this region is also required for the 
interaction between Ikaros and Foxp1 provides strong evidence that the interaction is 
directly involved in preventing the G2 arrest that results from Foxp1 overexpression. 
Importantly, these results suggest that alterations in the expression pattern of Ikaros 
isoforms such as IK6 have critical knock-on effects on Foxp1 transcriptional activity 
in vivo. 
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Figure 5.1 Rates of retroviral infection of B3 cells. B3 cells were infected with the 
retroviral constructs, as listed. Infection rates (as determined by GFP expression) are 
indicated in each panel. All experiments described in this chapter were performed 
three times. 
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Figure 5.2 (a) Cell Cycle Profile of infected B3 cells. Cell cycle status was assessed 
by propidium iodide (PI) staining 48 hours after infection. The flow cytometric pattern 
of a representative experiment is shown. A graphical representation of these results is 
shown in Figure 5.2 (b).  
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Figure 5.2 (b) Cell Cycle Profile of infected B3 cells. A graphical representation of 
the cell cycle profile of infected B3 cells is shown. These figures represent the average 
of three separate experiments. A marked increase in the proportion of cells in the G2 
phase of the cycle is observed following infection with Foxp1. This effect is abrogated 
by co-infection with WT Ikaros, but not by co-infection with Ikaros isoform IK6.  
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As with the previous co-expression experiments, it was important to confirm 
that the levels of ectopic FLAG-Foxp1 expression were similar in single and co-
infections. Protein expression was quantified following immunoblotting of extracts 
from retrovirally infected cells (Figure 5.3). The levels of each protein were 
determined using ImageQuant software (Fuji), and normalised to a loading control (β-
tubulin). The calculated molar ratios of each protein are shown in Figure 5.3. The 
levels of FLAG-Foxp1 were almost identical in the single infections and the co-
infections with either WT Ikaros (0.96) or IK6 (1.02), indicating that the absence of 
phenotypic ‘rescue’ is not caused by a differential reduction in FLAG-Foxp1 
expression when co-expressed with WT Ikaros or IK6. 
In addition, it was critical to verify that the amount of IK6 expression following 
IK6/Foxp1 co-infection was at least equivalent to the levels of WT Ikaros that 
‘rescued’ the cell cycle phenotype. In fact, the levels of IK6 that were present in IK6/ 
Foxp1 co-infection (1.51) were in excess of those found in the WT Ikaros/Foxp1 co-
infection (1.08). This indicates that the absence of phenotypic ‘rescue’ that is seen 
with IK6/Foxp1 co-infection is not simply a function of limited IK6 expression, 
relative to that of WT Ikaros. 
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Figure 5.3 Expression of FLAG-Foxp1 and HA-tagged Ikaros in infected B3 cells. 
The levels of ectopically expressed proteins were determined by immunoblotting of 
protein lysates extracted from infected B3 cells (upper panel) using ImageQuant 
software. Molar ratios of each protein (which were calculated following normalisation 
to an anti-β-tubulin loading control) are shown in the lower panel. Ratios are 
normalised to the levels of ectopically-expressed protein observed in the relevant 
single infection (i.e. infection with either WT Ikaros or Foxp1), which are given an 
arbitrary value of 1. 
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5.2 Co-infection with IK6 does not alter Foxp1-induced Gpr132 
expression in pre-B-cells 
As the cell cycle phenotype mirrored Gpr132 expression levels in the 
experiments described in Chapter 4, we predicted that the IK6 isoform would be 
unable to block Foxp1-mediated induction of Gpr132 expression. Levels of Gpr132 
were analysed in multiple QPCR assays using RNA from three separate experiments. 
Once again, expression of Gpr132 correlated very precisely with cell cycle phenotype 
(Figure 5.4), and consistent upregulation (between three- and seven-fold) of 
transcription was observed after Foxp1 infection. The mean increase in expression in 
all QPCR assays was 5.3 ± 0.45 (mean ± SEM). Co-infection of WT Ikaros with 
Foxp1 was associated with Gpr132 mRNA levels that were very similar (0.85 ± 0.07) 
to those seen with an empty vector control, consistent with the phenotypic rescue 
observed in previous experiments. In contrast, co-infection of IK6 with Foxp1 did not 
affect Gpr132 levels, which were very similar to those seen following single Foxp1 
infection (6.96 ± 0.58). Retroviral infection with IK6 alone had no significant effect 
on Gpr132 expression (0.99 ± 0.04). The differences in Gpr132 expression levels 
between WT Ikaros/Foxp1 co-infection and both Foxp1 single infection and 
IK6/Foxp1 co-infection were analysed using Student’s paired t-test, and were found to 
be highly statistically significant in each case (p < 0.001). 
Several additional observations can be made from the results shown in Figure 
5.4. Firstly, a decrease in Gpr132 expression was again seen following infection with 
WT Ikaros alone (0.58 ± 0.11), and this presumably reflects similar inhibition of the 
effects of endogeneous Foxp1 by ectopically-expressed WT Ikaros. Single infection 
with IK6 alone did not significantly alter Gpr132 expression levels, indicating that 
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any sequestration of endogeneous WT Ikaros by IK6 does not significantly inhibit 
Ikaros/ Foxp1 interaction in this setting. 
It is also notable that Foxp1-mediated induction of Gpr132 expression was 
higher in this set of assays (5.28 ± 0.45) than in the experiments described in Chapter 
4 (2.33 ± 0.6). It is most likely that these differences arise from improved infection 
efficiency in the latter set of experiments, and a consequent increase in Foxp1-
mediated effects. Although overall rates of GFP positivity were similarly high (at least 
95% in each case), the mean fluorescence intensity of the transduced cell population 
was approximately 10-fold higher in the more recent infections, and this was 
presumably associated with higher Foxp1 activity. This may also explain an extra 
phenotypic effect that was observed in the latter experiments, as Foxp1 infection was 
associated with an increase in the proportion of cells in G1 and a reduction in the 
proportion of cells in S-phase that had not previously been observed (Figure 5.2). This 
additional finding indicates potential further roles for Foxp1 in the regulation of genes 
that are involved in cell cycle progression, that were only evident in the context of 
further increases in Foxp1 activity. Further investigation of these processes was not 
possible in the course of the investigation described in this thesis, but it is important to 
note that the key original phenotypic observation (G2 arrest) was consistently found in 
all performed experiments. 
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Figure 5.4 Expression of Gpr132 in infected B3 cells. Expression analysis 
was carried out as described in Chapter 4. Foxp1 infection resulted in increased levels 
of Gpr132, which were ‘rescued’ by co-infection with WT Ikaros, but not Ikaros 
isoform IK6. Statistical significance was calculated using Student’s paired t test and is 
indicated above the graph columns. Error bars indicate standard error of the mean 
(SEM). Averages of QPCR assays of three biological replicates are shown. 
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5.3 Summary 
 The experiments reported in this chapter shed further light on the results 
described in Chapter 4, and on the mechanism of Ikaros/Foxp1 interaction. Increased 
Foxp1 activity in pre-B-cells resulted in clear phenotypic changes in lymphocyte cell 
cycle profile that were closely correlated with the expression of a key cell cycle 
molecule (G2A, encoded by the gene Gpr132). These effects were abolished by WT 
Ikaros (which interacts physically with Foxp1), but not by Ikaros isoform IK6 (which 
does not interact with Foxp1, as shown in Chapter 3). This demonstrates that rescue of 
the G2 arrest phenotype by WT Ikaros is not due to non-specific protein expression 
effects, as relatively higher levels of IK6 had no effect on Foxp1 activity. The 
correspondence between the requirement for the central zinc finger domain of Ikaros 
both for the physical interaction between the two proteins and for the block on Foxp1-
mediated enhancement of Gpr132 expression supports the idea that Ikaros exerts its 
effects on transcriptional regulation by Foxp1 through direct physical interaction. 
 
 
 
125 
 
Chapter 6 
Analysis of Foxp1 binding to the murine Gpr132 locus 
The experiments described in Chapters 4 and 5 have shown a close 
concordance between increases in Gpr132 transcription and the cell cycle phenotype 
that follows Foxp1 overexpression. The fact that the G2A protein product of the 
Gpr132 gene is known to induce G2 arrest when ectopically expressed in mammalian 
cells (Le et al., 2002; Weng et al., 1998) strongly suggests that the G2 arrest that was 
observed is a direct consequence of the induction of Gpr132 expression. 
We hypothesised that the G2 arrest and associated Gpr132 expression were 
dependent on binding of Foxp1 to regulatory sequences located within or close to the 
Gpr132 gene. The abolition of these effects by WT Ikaros would therefore rely upon 
direct contact with the Foxp1 forkhead region, which would inhibit DNA binding. 
Conversely, IK6 lacks the central zinc finger domain that is necessary for association 
with Foxp1 (Chapter 3) and so would not affect the amount of Foxp1 that is available 
for DNA interaction. 
In order to test this hypothesis experimentally, chromatin immunoprecipitation 
(ChIP) was performed. Chromatin was extracted from retrovirally infected B3 cells 
(from the same experiments that are described in Chapter 5) and subjected to IP with 
an anti-FLAG antibody, which precipitated the ectopically-expressed FLAG-Foxp1.  
Following reverse cross-linking and DNA purification, genomic regions in and around 
the Gpr132 gene were amplified by QPCR in order to determine the extent of Foxp1 
binding in the presence and absence of ectopic WT Ikaros and IK6.  
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6.1 Identification of gene regulatory elements at the Gpr132 locus 
 The Gpr132 gene consists of three coding exons and is located at mouse 
chromosome 12: 114,089,087-114,099,127 (July 2007 (NCBI37/mm9) Assembly). 
The regulatory elements that control Gpr132 expression have not been described in 
published literature, and it was therefore necessary to identify DNA regions in and 
around the gene locus at which Foxp1 might bind. 
Transcription factors bind to enhancer sequences that are often located close to 
the transcriptional start site, although regulatory regions may be located at varying 
distances both upstream and downstream of the gene (see Chapter 1.1). Recent 
advances in high-throughput genomics have generated large amounts of published 
experimental data that can be used for the identification of putative gene promoter and 
enhancer elements. For example, ChIP followed by massive parallel sequencing 
(ChIP-sequencing) has provided new evidence of the genome-wide patterns of histone 
modifications that are associated with enhancer location, including monomethylation 
of the lysine residue at position 4 of the N-terminal tail of histone H3 (H3K4me1). In 
addition, the presence of other histone modifications (such as trimethylation of H3K4) 
indicates active transcription that depends on contiguous transcription factor binding. 
Much of this information is freely accessible through publicly available databases 
such as the UCSC genome browser (http://genome.ucsc.edu), and this resource was 
found to be the most useful in the assessment of potential sites of Foxp1 binding near 
the Gpr132 locus. This database also integrates additional information that identifies 
possible transcription factor binding sites, such as locations of DNase 
hypersensitivity.  
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The strategy that was adopted involved searching the genomic sequence 
directly for specific putative Foxp1 binding sequences, which have been described to 
contain the core seven nucleotides TATTTRT (where R = any nucleotide) (Wang et 
al., 2003). The genomic sequence in and around the Gpr132 gene was searched for 
this motif, in both the sense and antisense directions. In silico examination of the 
sequence (depicted schematically in Figure 6.1) identified two particular regions of 
interest, which were designated Regions ‘A’ and ‘B’. The genomic sequences of these 
regions are shown in Figure 6.2. Region A lies approximately 4kb downstream of the 
transcriptional start site, and includes four putative Foxp1 binding sites, according to 
the previously described consensus sequence. Region B lies approximately 1kb 
upstream of the transcriptional start site, within the area where a gene enhancer might 
typically be expected. Region B contains one putative Foxp1 binding site, and has 
been associated with the presence of H3K4me1 in published ChIP-sequencing data. In 
addition, each region borders an area of reported DNase hypersensitivity in adult (8 
week-old) murine B-cells, which is suggestive of transcription factor binding. The 
extent of Foxp1 occupancy of these loci in retrovirally-infected B3 cells was assessed 
in ChIP experiments, which are described in the next section. 
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Figure 6.1 Location of the genomic regions amplified in Gpr132 ChIP.  A 
schematic representation of the Gpr132 locus is shown, with the scale depicted in 
bases. The locations of ChIP regions A and B are indicated with arrows. Coding exons 
are represented by filled boxes. TSS = Transcriptional start site.  
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Region A:  Mouse Chromosome 12:114,100,053-114,100,552 
GGCTTGGGGGTGTTGGCCCCATCCCTGACAGCTCCCAGAGTCCTCAAAACT
GAAGGCAAAGCTGGCTTGGTAGCCTGTGTTCAGCTAACACTTTCAGAAGC
GCTAGCCGACGAAGCCCAGCTTTACAGAGCAGTTTGAAAGGTCATGACCC
AGATAGCAGCTCCCTGCCTAAGTCCAAAGACAGACATGCTCTCTGAGAGT
CATGCCAGGCTTCAAGGCTGTGAGGCTGGAGGCCTTTCTTTCTCACCCAAC
CCCTAACAGACATTTACATATTTGTGTGGGTGGCAGTACAGTCCCTAGAAA
GCTGGCCCTCAGGGGTGTGGGGCAGACAGCTGGCATGCGGGCCTGAAGAT
AGTCCATCTTAACTTTCTGAAAGCAGCTGTTCGTGGGCCGTCGCCTTCAAG
GAATCTAGTGCACAGTAAGTCCTCCCTGGGCTCTGACCACGATGCCACTCG
TACCTGACCTTGGAGGGCAAAGGGGTTTGATGGCTCTGGCACAA 
 
 
Region B: Mouse Chromosome 12:114,094,726-114,095,225 
TACAGACAACCAGGCACCAGGGAGCATCAAAGCATCACCCTGGATACCAG
AGTTAAAACTGTTATTTGTTGGTTATGGTTGGCAAAGCTGATGGCACATGA
GCTCCCACAGAAGAATTAAGAGCTCCCAAAAGGCGAAGAAACGCAAAAT
CAGCATGAAGAACGGTCTCTTTGTTTTGTTTTGTTTTCCTGCCTATCAGGCT
GACAAAAATAACTAAATCAGTGTTCTGAAGTCTGAAGACATGGCACCCTG
AAGCTACACAACGGGGTGGTCACTAGGTACCAATATTTCAGAGCCCCACT
TTGCAGTCAGTTTCCAACACCGTTAAGAAAGTCTGAACTTGCTAAAATTCC
TCCTAGGGATTTTTTATTTCTGATTAAAAATAATGACCTGAAAAGTTAAGT
GTGTCTGACCTGCTGCCCACCTGCTCCCCCGACACACATGGCTGCCCCTCA
GCCAGGCAGATAACCACGGTATTTCCCCAGAGTGCATTGGGCCGC 
 
 
 
 
 
Figure 6.2 Genomic Sequences of Gpr132 ChIP Regions A and B. The sequences 
and genomic locations (July 2007 (NCBI37/mm9) Assembly) of Regions A and B that 
were amplified by QPCR following anti-FLAG ChIP of retrovirally infected B3 cells 
are shown. Putative Foxp1 binding sites are highlighted. 
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6.2 Examination of Foxp1 binding to the Gpr132 locus by 
Chromatin immunoprecipitation (ChIP) 
Chromatin was isolated from retrovirally infected B3 cells (see Section 2.12) 
and subjected to IP with an anti-FLAG antibody. IP of chromatin extracted from cells 
that had been infected with empty retroviral vector was performed concurrently, in 
order to provide a control for non-specific antibody precipitation. Following reverse 
cross-linking, pulldown of the sequences of Regions A and B was assessed by QPCR 
amplification. 
The retroviral infection experiments were associated with high levels of ectopic 
protein expression, which in turn led to a significant amount of baseline ‘background’ 
binding of FLAG-Foxp1 to chromatin. Our group has previously found that Foxp1 
tends to show relatively broad patterns of chromatin binding in ChIP experiments 
(Lieber, 2008 and Domaschenz, unpublished data), while Forkhead box proteins have 
been described to exhibit high-affinity non-specific binding to nucleosomes (Sekiya et 
al., 2009). Inclusion of an experimental control to allow for these effects was therefore 
very important, and was integral to accurate estimation of Foxp1 chromatin 
occupancy. 
Two genomic regions (here arbitrarily designated as Background Regions 1 
and 2) were used that to date have exhibited an absence of transcription factor binding 
in reported ChIP-sequencing data (Natalia Kunowska, personal communication). 
Background Region1 is located at mouse chromosome 17:86,190,215-86,190,285, 
while Region 2 is found at chromosome 4:55,591,773-55,591,842 (July 2007 
(NCBI37/mm9) Assembly). These sequences were assayed by QPCR following anti-
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FLAG ChIP, and the resultant levels of amplification (typically approximately 2% of 
input, henceforth referred to as ‘background’) were subtracted from the corresponding 
amplification figures for the test regions, in order to give a quantification of FLAG-
Foxp1 binding to Gpr132 Regions A and B.  
 The results of the ChIP experiments were concordant with Gpr132 
expression levels. Foxp1 bound strongly to both Regions A and B, at levels greatly in 
excess of background. Figure 6.3 shows the mean % input figures of five QPCR 
experiments, following subtraction of background. The separate control for non-
specific antibody pulldown (i.e. anti-FLAG IP of the empty vector infection) was 
associated with essentially no pulldown (typically < 10-5 % input), and these figures 
are not shown in the graph. In addition, the results of separate QPCR assays using 
different primer pairs that amplified the same genomic regions were also highly 
concordant (data not shown). 
Co-infection with WT Ikaros reduced the extent of Foxp1 binding to levels that 
were close to background in a highly reproducible manner (Figure 6.3). Co-infection 
with IK6 had minimal effects on Foxp1 binding, which remained very similar to the 
levels seen following Foxp1 infection alone. The differences between the amounts of 
binding that were seen following each retroviral infection were analysed by Student’s 
paired t-test and found to be statistically significant for all comparisons with WT 
Ikaros/ Foxp1 co-infection (see legend to Figure 6.3). 
Taken together, these data provide strong evidence that the reduction of 
Gpr132 expression when WT Ikaros is co-expressed with Foxp1 is the result of 
specific displacement of Foxp1 from enhancer elements a t the Gpr132 gene. This 
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finding provides a mechanistic explanation for the observed abrogation of the G2 
arrest phenotype that is seen following co-expression of WT Ikaros. 
 
 
 
Figure 6.3 ChIP analysis of binding of Foxp1 to the Gpr132 gene. Chromatin from 
B3 cells infected with different retroviral constructs (indicated below each bar) was 
precipitated with anti-FLAG antibody, and Gpr132 regions A and B (Figures 6.1 and 
6.2) were amplified by QPCR. Figures for % input were obtained after subtraction of 
background levels, as described in Section 6.2. The differences between WT 
Ikaros/Foxp1 co-infections and both Foxp1 single infection and IK6/Foxp1 co-
infections were analysed using Student’s paired t-test, and were found to be highly 
significant, as shown. The averages of QPCR assays of three biological replicates are 
shown. 
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6.3 Summary 
 The results of these ChIP experiments show that the extent of chromatin 
occupancy of Foxp1 is affected by altering the levels of its interaction partner, WT 
Ikaros. Foxp1 was found to bind specifically to the Gpr132 locus, as the ChIP values 
for control genomic regions (‘background’) were markedly lower. The effect of 
expressing WT Ikaros on the binding of Foxp1 to the Gpr132 was specific, as 
expression of relatively higher quantities of IK6 (Figure 5.3) had no effect on Foxp1 
occupancy of the Gpr132 locus. Unfortunately, attempts at demonstrating a similar 
phenomenon by electrophoretic mobility shift assay (EMSA) were unsuccessful, as 
poor binding of purified GST-Foxp1 to oligonucleotides was observed in vitro. 
These data provide compelling evidence that the interaction between Ikaros and 
Foxp1 directly affects the DNA-binding activity of Foxp1, and a coherent mechanism 
for the cell cycle and gene expression effects that were observed may therefore be 
suggested. Foxp1 binding to Gpr132 regulatory elements stimulates expression of the 
G2A protein which triggers G2 arrest. The effects of Foxp1 excess are abrogated by 
the presence of equivalent amounts of WT Ikaros, which occupies the DNA-binding 
domain of Foxp1, thereby preventing the upregulation of Gpr132 expression. IK6 has 
no effect on gene expression or the cell cycle phenotype, because it does not interact 
with Foxp1. The original model shown in Figure 4.1 may now be updated to 
incorporate the findings of the intervening experiments (Figure 6.4).  
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Figure 6.4 Updated model of the effects of protein imbalance on expression of 
gene targets. The upper panel depicts the effects of overexpression of Foxp1 (blue 
pies), which binds to DNA to activate Gpr132 expression. Co-infection of WT Ikaros 
(lower left panel) inhibits induction of Gpr132 expression through occupancy of the 
Foxp1 DNA-binding domain. Co-infection of IK6 (lower right panel) has no effect on 
the amounts of Foxp1 that bind DNA to induce Gpr132 expression. 
Gpr132
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+ WT Ikaros
Gpr132
+ IK6
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As with the original description of the model in Figure 4.1, this diagram shows 
one potential ramification of an imbalance in factor levels, and several other outcomes 
are possible. For example, this model would be invalidated in the context of a gene 
locus where Ikaros and Foxp1 binding are not mutually exclusive, as corresponding 
effects on Ikaros regulation of gene targets would be expected to confound the output. 
We have however excluded this possibility by examination of ChIP-sequencing data 
that were published by collaborators in our institute (Ferreiros-Vidal et al., 2013), as 
Ikaros was not found to bind to the Gpr132 locus in an identical B3 cell system to that 
used in the experiments I have described. 
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Chapter 7 
 Discussion 
Ikaros and Foxp1 have been established as key regulators of B-cell 
differentiation and proliferation (Georgopoulos et al., 1994; Hu et al., 2006). 
Mutations and/ or deletions in both proteins are also strongly implicated in lymphoid 
malignancy, including B-ALL (Brown et al., 2008; Mullighan and Downing, 2008; 
Put et al., 2011; Sagaert et al., 2006). The work described in this thesis has 
characterised a hitherto unrecognised physical and functional interaction between 
these factors. The physical association between the proteins is direct, and requires the 
DNA-binding domains of both molecules, as shown by the results of the experiments 
reported in Chapter 3. 
The normal functions and patterns of expression of each protein and the 
locations of the domains that mediate the interaction between them raised the 
possibility that they might affect one another’s functioning. This effect could be 
synergistic, with the interaction affecting the specificity or degree of DNA binding. 
Alternatively, the effect could be antagonistic, with contact between the two binding 
domains blocking binding of either or both factors to transcriptional regulatory 
elements. In addition, the interaction between the proteins may be necessary for 
recruitment of other factors that are involved in the modulation of gene expression, 
such as transcriptional activators or repressors. 
The experimental findings detailed in Chapters 4-6 demonstrate that at least 
one type of effect is antagonistic. Overexpression of Foxp1 in a pre-B cell line 
resulted in increased transcription of Gpr132, which encodes the G-protein coupled 
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receptor G2A protein that is known to cause G2 cell cycle arrest in mammalian cells 
(Weng et al., 1998). Foxp1-mediated induction of Gpr132 expression and phenotypic 
cell cycle arrest were both reversed by co-expression of WT Ikaros, which was shown 
to block binding of Foxp1 to sequences in and around the Gpr132 gene. This indicates 
that the abrogation of Foxp1-mediated effects is contingent upon direct inhibition of 
binding of the protein to DNA regulatory sequences. 
Co-expression of the Ikaros isoform IK6 had no effect on the cell cycle 
phenotype, Gpr132 expression levels, or Foxp1 binding to chromatin. These results 
strongly suggest that the inhibition of Foxp1-related effects is dependent on direct 
protein-protein contact that follows restoration of the equilibrium between the relative 
amounts of Ikaros and Foxp1 proteins. In addition, this finding provides further 
evidence for the mediation of protein contact through the Ikaros central zinc finger 
domain in vivo. 
These novel findings provide important new insights into the roles of Ikaros 
and Foxp1 in the maintenance of cell cycle homeostasis in B-lymphocytes. In the final 
section of this thesis, I will discuss how the functional implications of the interaction 
might be further elucidated (Section 7.1), and how these results may contribute to the 
understanding of normal physiological (Section 7.2) and pathological (Section 7.3) 
lymphoid cell cycle regulation. 
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7.1 Functional consequences of the Ikaros-Foxp1 interaction 
As both Ikaros and Foxp1 are expressed at high levels from the early stages of 
B-lymphopoiesis (Georgopoulos et al., 1994; Wang et al., 2003), the data described in 
this thesis strongly suggest that interaction between these factors could contribute to 
the regulation of a number of genes during the course of B-cell development. By 
extension, this suggests that fluctuations in the relative amounts (and patterns of 
isoform expression) of each protein at different stages of differentiation contribute to 
cellular phenotype. 
Intuitively, occupation of the DNA-binding domain of a transcription factor by 
another protein might be expected to inhibit factor binding to gene targets. In keeping 
with this hypothesis (as shown in Figures 4.1 and 6.4), we have shown that one effect 
of the interaction between the proteins is antagonistic, as Ikaros directly blocked 
binding of Foxp1 to putative regulatory elements of the Gpr132 gene. Our findings do 
not however preclude the occurrence of different effects at other gene loci. Protein-
protein association has been described to induce conformational changes that enhance 
transcription factor activity (Nagulapalli et al., 2002), and it is also possible that the 
presence and/ or recruitment of additional molecules at other genomic sites (or in 
other cell types) may result in enhanced binding of one or both factors to DNA. 
Elucidation of the full spectrum of functional consequences of Ikaros-Foxp1 
interaction may be provided by experimental approaches that comprehensively 
examine the global range of transcription factor activity, using unbiased approaches. 
For example, gene expression analysis by microarray would clarify the range of 
Foxp1 transcriptional effects in B-lymphoid cells, while ChIP-sequencing would 
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provide a comprehensive picture of the genome-wide patterns of Foxp1 binding at 
differing levels of protein expression. Integration with published measurements of 
Ikaros binding patterns (Zhang et al., 2011, Ferreiros-Vidal et al., 2013) should 
identify further putative targets that may be influenced by the protein-protein 
association, particularly if the reciprocal effect (i.e. Foxp1 blocking Ikaros binding to 
DNA) also affects transcriptional regulation. Further clarification of the influences of 
Ikaros-Foxp1 interaction on the dynamics of factor binding would also be provided by 
experimental models in which the expression of one or both factors is suppressed 
either by genetic knockout or RNA interference.   
There is a precedent for interaction between Ikaros family members and 
Forkhead transcription factors, as Eos (a widely-expressed Ikaros family member) and 
Foxp3 were found to associate directly in CD4+ Regulatory T-cells in a study that was 
published during the course of this work. This interaction was shown to be critical for 
recruitment of transcriptional repressors and Foxp3-mediated gene silencing (Pan et 
al., 2009). No interaction was observed between Foxp3 and Ikaros in these 
experiments. In contrast to the antagonistic interaction that was observed between 
Ikaros and Foxp1 in this thesis, the interaction between Eos and Foxp3 seems to be 
synergistic, as Eos was shown to be essential for recruitment of transcriptional 
repressors and gene silencing by Foxp3. 
A key difference between the Eos-Foxp3 interaction and the Ikaros-Foxp1 
interaction is the location of the domains of protein association. The region that is 
necessary for interaction with Eos is located some distance away from the Foxp3 
forkhead domain, in the N-terminal region of the protein. Similarly, the C-terminal 
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portion (300 amino acids) of Eos was found to be sufficient for interaction with 
Foxp3, indicating that the DNA-binding region is not required for protein-protein 
contact. This suggests that the Ikaros-Foxp1 and Eos-Foxp3 interactions arose 
separately during the evolution of immune regulation, and are not related functionally. 
It would be worthwhile to investigate the existence of any further interactions 
between Forkhead proteins and Ikaros family members, as the latter proteins exhibit 
significant structural homology. In particular, the existence of an interaction with 
other Ikaros proteins could provide mechanistic insight into the regulation of the cell 
cycle at differing stages of B-cell differentiation. For example, fluctuations in the 
amounts of Aiolos are known to directly affect cell cycle exit at the pre-B cell stage 
(see Section 1.4.2), and the existence (or otherwise) of an interaction with Foxp1 
would have implications for the mechanism of Aiolos-mediated effects. 
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7.2 Ikaros and Foxp1 regulate the cell cycle of pre-B-cells 
Regulation of the cell cycle is crucial for orderly progression of B-
lymphopoiesis (Jumaa et al., 2005). In particular, cell cycle exit is required for 
differentiation from the large pre-B-II stage (which is characterised by high rates of 
cell cycling and proliferation that are mediated by the pre-BCR) to the small, non-
cycling pre-B stage. Ikaros is known to modulate the lymphocyte cell cycle at this 
developmental transition, as Ikaros-mediated repression of c-myc transcription has 
been shown to be involved in triggering G1 arrest and cell cycle exit (Ma et al., 2010). 
To our knowledge, Foxp1 has not previously been described to directly affect 
the cell cycle of B-lymphocytes, although it has been shown to promote T-cell 
quiescence through transcriptional repression of the IL-7 receptor α-chain gene 
(IL7Rα) (Feng et al., 2010; Feng et al., 2011).  This does not preclude an alternative 
function in B-cells, as the effects of Foxp1 on cellular proliferation appear to be 
tissue-specific, being either pro- (Rao et al., 2010) or anti-proliferative (Zhang et al., 
2010), depending on cellular context, as detailed in Section 1.5. 
Further characterisation of the role of Foxp1 in B-lymphocyte cell cycle 
regulation is necessary, in light of the clear phenotypic effects that were observed 
following modulation of protein expression in these experiments. The fact that Foxp1-
induced G2 arrest can be overcome by co-expression of equivalent amounts of Ikaros 
suggests that maintenance of homeostatic levels of Ikaros and Foxp1 could be 
necessary for normal progression of pre-B cells through the G2/M stages of the cell 
cycle. The additional observation of G1 arrest at higher levels of Foxp1 expression 
also suggests that the Ikaros-Foxp1 interaction may influence gene expression at 
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several stages of the cell cycle. Again, clarification of the influence of the interaction 
on the cell cycle phenotype of haematopoietic cells would be provided by knockdown 
experiments as discussed in Section 7.1.  It would also be interesting to examine the 
later effects of Foxp1 overexpression in pre-B-cells, as all functional analyses that 
were described in B3 cells were performed 48 hours after infection, at which point all 
available cells were harvested for testing. In particular, it would be important to 
clarify whether the described cell cycle effects influence cellular viability and/ or 
differentiation. 
The data described here show that Foxp1-induced G2 arrest is clearly 
corrrelated with upregulation of Gpr132 expression, and the observed cellular 
phenotype is consistent with previous reports of this gene’s function. Gpr132 encodes 
the G2A protein, a G-protein coupled receptor for oxidised free fatty acids 
(Kabarowski et al., 2001). G2A is known to induce G2 cell cycle arrest when 
overexpressed in NIH 3T3 cells, although the consistency of this effect between cell 
types has not been established. For example, overexpression of the protein in 
keratinocytes produces a different phenotype, as a G1 block is seen (Obinata and 
Izumi, 2009). Normal tissue expression of Gpr132 is highest in haematopoietic cells,  
including both T- and B-lymphocytes (Weng et al., 1998). G2A has been reported to 
inhibit lymphocyte proliferation, as G2A-deficient mice have hyperproliferative T-
cells and develop an autoimmune syndrome in adult life (Le et al., 2001). This effect 
is consistent with the observation of decreased cellular proliferation of Foxp1-infected 
cells in the experiments described in this thesis. 
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Knowledge of the normal function of G2A in haematopoietic cells is lacking, 
although recent evidence suggests an involvement in modulation of macrophage 
activation (Bolick et al., 2009; Frasch et al., 2011). The downstream effects of G2A 
(and any activation of cell cycle related molecular pathways) are poorly understood. 
Our results suggest a potential role for G2A in regulating the cell cycle in normal 
lymphocytes; in particular, the hypothesis that suppression of Gpr132 expression may 
be necessary for progression of pre-B cells through G2 requires further investigation, 
and this would be provided by experiments in which the expression of Gpr132 is 
suppressed by RNA interference. Conversely, manipulation of Gpr132 levels by 
overexpression would be predicted to trigger cell cycle arrest of pre-B-cells, if the 
hypotheses described herein are correct.  
 
 
7.3 Loss of interaction between Ikaros and FOXP1 may contribute 
to chemotherapeutic resistance in B-ALL 
As human Ikaros and FOXP1 exhibit similar patterns of inter-protein 
association to their murine counterparts (Chapter 3), it is likely that the interaction 
between the proteins is also important for regulation of cell cycle progression in 
human B-cells. By extension, disruption of this interaction would be expected to result 
in altered cell cycle control and perturbation of B-lymphopoiesis. The results 
described in this thesis therefore have relevance for the elucidation of the downstream 
effects of quantitative imbalances of transcription factors that characterise lymphoid 
malignancy. 
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This is especially pertinent in the consideration of Ph+ B-ALL, which is 
characterised by expression of the BCR-ABL oncogene and by a poor long-term 
prognosis. This leukaemia is associated with high rates of genomic deletion of IKZF1, 
which result in expression of IK6 and reduced levels of full-length WT Ikaros 
(Mullighan et al., 2008). Both of these changes would be predicted to increase the 
amounts of FOXP1 available for induction of expression of target genes such as 
GPR132. We therefore propose that FOXP1-mediated effects could be important for 
the pathogenesis of these leukaemias. Importantly, IKZF1 deletion is associated with 
similar gene expression profiles in both Ph+ and non Ph+ B-ALL, suggesting that 
similar mechanisms of transcriptional dysregulation may contribute to 
leukaemogenesis, independent of the effects of BCR-ABL (Mullighan and Downing, 
2008). 
Previously published data have suggested a functional interplay between BCR-
ABL and G2A. GPR132 was originally identified in a search for genes that were 
transcriptionally upregulated by p185 BCR-ABL, and forced expression of G2A was 
shown to antagonise the transformative effects of BCR-ABL in vitro (Weng et al., 
1998). In keeping with these observations, G2A was shown to have a negative effect 
on in vivo leukaemic cell proliferation in a mouse model of Ph+ALL (Le et al., 2002). 
The effects of G2A deficiency on cell cycle profile were not reported in this study. 
The authors of this paper speculated that increased G2A expression in Ph+ALL was a 
favourable prognostic indicator, as it should lead to a diminished leukaemic cell mass. 
It is however also possible that these anti-proliferative effects actually confer a 
negative prognosis, as G2A may increase leukaemic cell resistance to 
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chemotherapeutic agents which are preferentially toxic to rapidly-dividing cells. In 
addition, G2 cell cycle arrest is believed to contribute to chemotherapeutic resistance 
in haematological malignancy, as delay of G2/M transition provides additional time 
for repair of DNA damage that might otherwise trigger cell death at the mitotic 
checkpoint (Bedi et al., 1995). The mechanism by which G2 arrest occurs in these 
leukaemias is currently poorly understood. Attempts were made to recapitulate this 
described G2 arrest by treating ALL cell lines with a number of chemotherapeutic 
agents, however the global cell cycle toxicity that was observed precluded targeted 
analysis.  
Our results suggest that upregulation of GPR132 as a result of increased 
FOXP1 activity that is consequent upon IKZF1 deletion could result in G2 arrest in 
these leukaemias, which in turn might contribute to treatment resistance and poor 
prognosis. If this is correct, it should be possible to demonstrate increased levels of 
GPR132 expression in IKZF1-deleted ALL. Preliminary assays performed by our 
laboratory and collaborators have however failed to show any correlation between 
IKZF1 deletion and GPR132 levels in either ALL cell lines or primary patient samples 
(data not shown). This might suggest that the expression of GPR132 is influenced by 
additional factors in ALL cells. Murine and human G2A are known to differ in 
activity, particularly with respect to ligand specificity (Radu et al., 2005), and it is 
probable that the regulation of GPR132 expression differs between the species. It may 
also be the case that these results fail to show a correlation between IKZF1 deletion 
and G2A expression because of the timing of the analysis. QPCR was performed on 
material isolated from diagnostic samples, and it is possible that FOXP1-mediated 
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GPR132 induction may only become pathologically relevant under conditions of 
cellular stress (for example, following chemotherapy). These results do not preclude a 
functional importance for G2A in IKZF1-deleted ALL, and further work is necessary 
to examine the potential role of this molecule in the regulation of the pathologically 
subverted lymphoid cell cycle. In particular, analysis of the cell cycle of IKZF1 wild-
type and deleted ALL cells (and correlation with any changes in FOXP1-mediated 
gene regulation and DNA-binding patterns that might exist) would provide insight 
into the effects of Ikaros protein levels on this aspect of cellular phenotype. The work 
described in this thesis will hopefully provide the impetus for new avenues of research 
in this area that may ultimately lead to better treatments for this disease.  
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